|  |
| --- |
| DRAFT Listed medicines evidence guidelines |
| How to demonstrate the efficacy of listed medicines |
| Version 4.0, March 2022 |

Copyright

© Commonwealth of Australia 2022  
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <[tga.copyright@tga.gov.au](mailto:tga.copyright@tga.gov.au)>.

Contents

[DRAFT Listed medicines evidence guidelines 1](#_Toc96958000)

[1 Introduction 6](#_Toc96958001)

[1.1 Purpose and scope of these guidelines 6](#_Toc96958002)

[1.2 Sponsors’ legal responsibilities 8](#_Toc96958003)

[1.3 The purpose of a sponsor’s evidence package 9](#_Toc96958004)

[1.4 When and how the TGA reviews efficacy 9](#_Toc96958005)

[2 How to find evidence 11](#_Toc96958006)

[2.1 Different types of evidence 11](#_Toc96958007)

[2.1.1 Evidence of traditional use 11](#_Toc96958008)

[2.1.2 Scientific evidence 13](#_Toc96958009)

[2.2 Literature searches 15](#_Toc96958010)

[2.2.1 When a literature search can be conducted 15](#_Toc96958011)

[2.2.2 Types of literature searches 16](#_Toc96958012)

[3 How to assess evidence 23](#_Toc96958013)

[3.1 How to assess if evidence is relevant 23](#_Toc96958014)

[3.1.1 Health benefit stated in literature 23](#_Toc96958015)

[3.1.2 Active ingredient 24](#_Toc96958016)

[3.1.3 Frequency and duration of use 26](#_Toc96958017)

[3.1.4 Target Population 26](#_Toc96958018)

[3.2 How to assess the quality of evidence 29](#_Toc96958019)

[3.2.1 Assessing the quality of evidence of traditional use 30](#_Toc96958020)

[3.2.2 Assessing the quality of scientific evidence 30](#_Toc96958021)

[4 How to use evidence 36](#_Toc96958022)

[4.1 Differences between claims and indications 36](#_Toc96958023)

[4.1.1 Indications 36](#_Toc96958024)

[4.1.2 Claims 37](#_Toc96958025)

[4.2 Types of indications 37](#_Toc96958026)

[4.2.1 Traditional indications 37](#_Toc96958027)

[4.2.2 Scientific indications 39](#_Toc96958028)

[4.2.3 Cross-paradigm indications 39](#_Toc96958029)

[4.3 Level of indications 40](#_Toc96958030)

[4.3.1 Non-specific indications 41](#_Toc96958031)

[4.3.2 Specific indications 41](#_Toc96958032)

[4.4 What types of evidence are expected for each type of indication? 48](#_Toc96958033)

[4.4.1 Using ‘clinically proven’ in your indications 50](#_Toc96958034)

[4.4.2 Vitamin/ mineral/ nutrient supplementation 50](#_Toc96958035)

[4.4.3 Biomarker indications 52](#_Toc96958036)

[4.4.4 Weight loss indications 53](#_Toc96958037)

[5 How to document and present evidence 57](#_Toc96958038)

[5.1 Critical appraisal of the body of evidence 58](#_Toc96958039)

[5.1.1 Critical appraisal 58](#_Toc96958040)

[5.1.2 Balanced view of the evidence landscape 58](#_Toc96958041)

[5.1.3 Justifications in your critical appraisal 59](#_Toc96958042)

[Appendices 61](#_Toc96958043)

[Appendix 1: Examples of resources and texts 61](#_Toc96958044)

[Appendix 2: Case studies 62](#_Toc96958045)

[Case study 1: Health benefit does not match 62](#_Toc96958046)

[Case study 2: Active ingredient dose does not match 62](#_Toc96958047)

[Case study 3: Active ingredient dose does not match 63](#_Toc96958048)

[Case study 4: Preparation method does not match 64](#_Toc96958049)

[Case study 5: Preparation method (raw) does not match 64](#_Toc96958050)

[Case study 6: Dosage form does not match 65](#_Toc96958051)

[Case study 7: Relevant evidence source 65](#_Toc96958052)

[Case study 8: Relevant evidence sources 66](#_Toc96958053)

[Case study 9: Relevant evidence sources 67](#_Toc96958054)

[Case study 10: Evidence not relevant and/or insufficient quality 68](#_Toc96958055)

[Case study 11: Evidence not relevant and/or insufficient quality 69](#_Toc96958056)

[Case study 12: Evidence sufficient 70](#_Toc96958057)

[Case study 13: Appropriate justification 70](#_Toc96958058)

[Case study 14: Non-validated measurement method 71](#_Toc96958059)

[Case study 15: Study duration inconsistent 71](#_Toc96958060)

[Appendix 3: Example evidence package for vitamin B12 73](#_Toc96958061)

**List of Figures**

[Figure 1: Overview of the ‘walk-through’ process to compile an evidence package 7](#_Toc96958062)

[Figure 2: Structure of these guidelines 7](#_Toc96958063)

[Figure 3: the difference between "AND" and "OR" Boolean operators 19](#_Toc96958064)

[Figure 4: Is your evidence source relevant to your medicine and indication? 28](#_Toc96958065)

[Figure 5: Decision tool for determining specific/non-specific indications 45](#_Toc96958066)

[Figure 6: Process for determining the evidence sources to include in an evidence package 60](#_Toc96958067)

**List of Tables**

[Table 1: Study populations 27](#_Toc96958068)

[Table 2: Hierarchy of scientific evidence sources based on risk of bias 29](#_Toc96958069)

[Table 3: Summary of specific and non-specific indications 42](#_Toc96958070)

[Table 4: Minimum evidence requirements for scientific and traditional indications 49](#_Toc96958071)

[Table 5: Minimum evidence requirements of supplementation claims and two permissible indications 51](#_Toc96958072)

[Table 6: Terms that should not be substituted for the term ‘weight loss’ in an indication 56](#_Toc96958073)

[Table 7: Summary of scientific evidence to support weight loss 56](#_Toc96958074)

# Introduction

## Purpose and scope of these guidelines

Under the Australian regulatory framework for therapeutic goods, the following types of medicines are included in the Australian Register of Therapeutic Goods (ARTG):

* Listed medicines:
  + Listed medicines (have an ARTG identification number starting with AUST L)
  + Assessed listed medicines [have an ARTG identification number starting with AUST L(A)]
* Registered medicines (have an ARTG identification number starting with AUST R)

The ‘Listed medicines evidence guidelines’ (these guidelines) relate to the evidence requirements for demonstrating the efficacy of listed medicines (AUST L) only.

|  |  |
| --- | --- |
| Information | **Note**:  While sunscreens and assessed listed medicines are types of listed medicines, their evidence requirements are provided separately in:   * [Assessed listed medicines evidence guidelines](https://www.tga.gov.au/publication/assessed-listed-medicines-evidence-guidelines) * [The Australian Regulatory Guidelines for Sunscreens](https://www.tga.gov.au/resource/australian-regulatory-guidelines-sunscreens-args#:~:text=The%20Australian%20Regulatory%20Guidelines%20for%20Sunscreens%20%28ARGS%3B%20the,%28the%20Act%29%20as%20at%20the%20date%20of%20publication.) |

Under the Australian regulatory framework for therapeutic goods, listed medicines (e.g.,., herbal supplements, vitamins and minerals) pose a lower risk to consumers than registered medicines (e.g.,., prescription medicines) based on the ingredients and/or indications that listed medicines can make.

Before using these guidelines, sponsors are expected to have an understanding of the underpinning legislation for the regulation of medicines in Australia. For more information refer to The [Australian Regulatory Guidelines for Listed Medicines and Registered Complementary Medicines](https://www.tga.gov.au/publication/australian-regulatory-guidelines-listed-medicines-and-registered-complementary-medicines) (ARGLM & RCM). In particular, [General guidance for listed medicines](https://www.tga.gov.au/resource/general-guidance-listed-medicines) and [Permitted indications for listed medicines guidance](https://www.tga.gov.au/publication/permitted-indications-listed-medicines-guidance) provide important background information on the regulatory framework for listed medicines.


These guidelines step through the critical analysis a sponsor (person legally responsible for the listed medicine in Australia) is expected to perform on their collated evidence to demonstrate the efficacy of their medicine.

Sponsors may choose to generate their own scientific evidence for their listed medicine (e.g.,. conduct a clinical trial on their unique formulation) or they may choose to rely on existing published literature. These guidelines are primarily for sponsors who base their medicine’s efficacy on publicly available published literature. It is intended to assist these sponsors to:

1. Find evidence
2. Critically assess evidence
3. Select indications (as [permitted for use in listed medicines](#_Indications)) based on evidence
4. Present evidence

An evidence package is expected to contain a persuasive critical appraisal of the collated body of evidence to demonstrate a listed medicine’s efficacy. **Figure 1** shows the steps that are involved in compiling an evidence package. Note that this ‘walk-through’ approach is based on the scenario where sponsors select a research question first, researches the evidence landscape and then selects therapeutic indications based on the evidence they find. An alternative approach that sponsors may choose is to first select the indication/s for their medicine and then survey the evidence landscape.

Figure : Overview of the ‘walk-through’ process to compile an evidence package



The overall structure of these guidelines is summarised in **Figure 2**.

Figure : Structure of these guidelines

Figure 1 provides the structure of the guidelines.


|  |  |
| --- | --- |
| Information | **Note:**  **TGA disclaimers**   * This document is a guide only. * It is the responsibility of each sponsor to understand and comply with the regulatory requirements contained in the *Therapeutic Goods Act 1989* (the Act) and supporting regulations. You are encouraged to seek your own professional advice on how therapeutic goods legislation and other applicable laws apply to you. * These guidelines reflect what the TGA would consider when assessing whether the efficacy of a listed medicine is acceptable. However, there may be individual circumstances that justify a departure from these guidelines and in this situation the TGA will consider the merits of each case against the regulatory requirements. |

## Sponsors’ legal responsibilities

Listed medicines do not undergo a pre-market assessment of safety, quality and efficacy by the TGA and as such, are not ‘approved’ by the TGA. Rather, listed medicines are entered in the ARTG under section 26A of *Therapeutic Goods Act 1989* (the Act) following an application and legal certification by the sponsor that their medicine meets all the applicable legislative requirements, including that the medicine:

* only contains pre-approved low-risk ingredients from a list of TGA approved permissible ingredients known as the [Permissible Ingredients Determination](https://www.tga.gov.au/therapeutic-goods-determinations)
* only makes low-level indications selected from a list of TGA approved permitted indications known as the [Permissible Indications Determination](https://www.tga.gov.au/therapeutic-goods-determinations) (see section [4.1.1 Indications](#_Indications) for more information on indications permitted for use in listed medicines)
* is manufactured in accordance with the principles of good manufacturing practice

In relation to the **efficacy of listed medicines**, sponsors:

* certify [against subparagraph 26A(2)(ja) of the Act] that they hold evidence to support all indications for their medicine and comply with all requirements for those indications in the [Permissible Indications Determination](https://www.tga.gov.au/therapeutic-goods-determinations)
* certify [against subparagraph 26A(2)(j) of the Act] that they hold evidence to support any claims (that are not indications) made for the medicine (refer to [4.1 Differences between claims and indications](#_Indications_and_claims))
* adhere to the condition of listing [provided in subparagraph 28(7) of the Act) that they must, at all times while the medicine remains listed, hold information/evidence that supports the indications

A medicine can be cancelled from the ARTG by the TGA, among other things, if (note that this is not an exhaustive list):

* the sponsor certifications under 26A(2)(ja) and (j) of the Act (that the sponsor holds evidence for all indications and claims) are found to be incorrect
* the efficacy of the medicine appears to be unacceptable [paragraph 30(2)(a) of the Act]

|  |  |
| --- | --- |
| Information | **Note: Efficacy vs effectiveness**[[1]](#footnote-1)  **Efficacy –** is the capacity to produce an effect. In medicine, it is the ability of an intervention or medicine to produce a desired effect in expert hands (e.g., a health professional) and under ideal circumstances.  **Effectiveness** – is the capability of producing a desired result. In medicine, effectiveness relates to how well an intervention or medicine works in practice, as opposed to efficacy, which measures how well it works in randomised controlled trials or laboratory studies. |

## The purpose of a sponsor’s evidence package

Based on the legal responsibilities outlined in [1.2 Sponsors’ legal responsibilities](#_Why_sponsors_have), the overall purpose of an evidence package is for the sponsor to demonstrate to the TGA that your medicine will do what its indications say it will do (i.e. your medicine is efficacious).

It is up to the sponsor to decide how to demonstrate this. These guidelines explain the elements that the TGA considers when determining whether the medicine’s efficacy is acceptable.

However, it must be acknowledged that there is no ‘one size fits all’ approach and these guidelines cannot provide for all possible scenarios. Efficacy reviews by the TGA are undertaken on a case-by-case basis and assessed on individual merit. A sponsor may choose to diverge from these guidelines as long as their evidence package demonstrates to the TGA that their medicine’s efficacy is acceptable. As such, it is important that an evidence package includes a persuasive critical analysis of the body of evidence.

## When and how the TGA reviews efficacy

We conduct random and targeted post market compliance reviews of listed medicines on an ongoing basis. At any time, the TGA can request that a sponsor provides the evidence they hold to show that they meet their legal responsibilities as outlined in [1.2 Sponsors’ legal responsibilities](#_Why_sponsors_have).

As part of a post market compliance review, we may undertake an efficacy review to check:

* the accuracy of the sponsor certification that they hold evidence to support all indications and claims made for the medicine
* that the evidence the sponsor holds supports the indications at all times the medicine remains listed
* the efficacy of the medicine is acceptable
* whether the presentation of the medicine suggests it has characteristics it does not have
* whether advertising for the medicine includes indications that are not included in the ARTG

During an efficacy review, the key questions the TGA considers include (but are not limited to):

1. What therapeutic effect is described by the indication?
2. On what basis can it be concluded that the medicine will result in this therapeutic effect? What are the reasons for this conclusion?
3. Is the above conclusion based on data or information that we have confidence in to be true and accurate?
   1. If assumptions have been made, are these valid?
   2. Does the data result from biases that impact on their validity?
   3. Is there competing data? If yes, which dataset best represents what the medicine will do?

Sponsors should consider the answers to the above questions when critically analysing the body of evidence compiled in their evidence package in order to demonstrate to the TGA that their medicine is efficacious and meets the legal requirements as outlined in [1.2 Sponsors’ legal responsibilities](#_Why_sponsors_have).

# How to find evidence

This section outlines the different types of evidence that can be sourced and provides guidance on how to conduct a literature search. A literature search is usually the first step to identify evidence sources to include in an evidence package for a listed medicine.

## Different types of evidence

There are two types of evidence that can be used to demonstrate efficacy of listed medicines:

* evidence of traditional use
* scientific evidence

An evidence package can include scientific evidence and/or traditional evidence with the appropriate corresponding permitted indications (see [4.1.1 Indications](#_Indications) for information on indications permitted for listed medicines).

While most listed medicine sponsors rely on existing published literature, some sponsors may choose to generate their own scientific evidence for their medicine e.g.,. conduct a clinical trial. In such cases, sponsors should follow the appropriate guidelines for clinical trials to ensure the data is robust.

### Evidence of traditional use

Traditional medicines are based on an extensive history of use, often measured over thousands of years. This history provides an accumulated repository of systematic observation and underpins the safe use of these medicines in a traditional setting. Usually when a medicine or a relevant ingredient in the medicine has been used over a long period of time, the dosage and formulation have been refined to maximise therapeutic effectiveness and minimise risk.

Many traditional medicines and ingredients with a long and coherent history of use are well documented in pharmacopoeias, monographs, materia medica, other texts and information published by various international regulatory authorities.

Some traditional medicine paradigms have been recorded by people outside the tradition’s indigenous origin and culture. Other traditional medicine paradigms, particularly those that have been developed within smaller and more localised groups, are not well documented; rather they are based on knowledge transmitted orally from generation to generation.

For many traditional medicines there has been little quantifiable scientific research, scientific assessment or scrutiny undertaken on the medicine’s mode of action or effect. Therefore, traditional use claims cannot support a scientific claim of efficacy, a mechanism of action or an underlying physiological process, as these require support by quantifiable scientific evidence.

Factors that should be considered to establish that a medicine or active ingredient has a well-established tradition of use for its intended purpose include:

* the time over which the medicine or active ingredient has been used
* therapeutic use/s during that time
* continuity of its use
* geographical extent of its use
* use of the medicine is recorded in recognised traditional medicine evidence sources

A well-established tradition of use is based on:

* evidence of a history of widespread medicinal use of the ingredient/s or medicine that exceeds three generations of use (75 years)
* the traditional use is extensively recorded in internationally recognised evidence sources for traditional medicine use

|  |  |
| --- | --- |
| Information | **Note:  Homoeopathic medicine**  Homoeopathic medicine is a traditional paradigm where the manufacturing process (of serial dilution and succussion or serial trituration) is a major component of the tradition of use. Provided that a substance is prepared according to principles that are described in a recognised homoeopathic pharmacopoeia and safety requirements are satisfied, indications may be based on traditional use. Evidence of traditional use for homoeopathic medicines can include independent written histories of use in traditional or contemporary homoeopathic literature. |

#### Evidence sources of traditional use

Evidence to demonstrate efficacy of listed medicines with traditional indications can be derived from sources such as:

* materia medica
* official pharmacopoeias
* monographs
* publications from various international regulatory authorities
* texts that are relevant to the traditional paradigm
* well-recognised evidence-based reference texts

A **pharmacopoeia** contains a comprehensive list of medicines and describes their properties and how they are prepared.

A **materia medica**sets out the body of knowledge on the therapeutic properties of medicines. Different materia medicarelate to different types of complementary medicines, for example: Traditional Chinese Medicine, homoeopathy.

While the TGA does not have a list of approved sources of information, [Appendix 1](#_Appendix_2:_Examples) provides some examples of internationally recognised resources and texts.

#### Other sources of evidence for traditional use

***Non-reference textbooks***

Non-reference textbooks cite, comment on, or build on established sources of evidence and thus do not usually provide sufficient evidence to substantiate traditional indications. If a non-reference textbook is used, the original source of evidence of traditional use should be located from the original documents cited in footnotes. If this is not possible, then the evidence package should include footnotes to clearly indicate that the textbook is based on original historic records or studies.

Where it is not possible to find the original reference that describes the traditional use, efficacy may be supported by more recent references reporting the original traditions of use. However, these references should provide enough information to support that the medicine is consistent, as far as possible, with the one described in the original reference.

***Modern textbooks and monographs***

Many modern textbooks and monographs include a combination of both traditional and scientific evidence. If using a textbook, monograph, or similar source to in your evidence package, it must be determined whether the information in the source is traditional or scientific.

In a situation where a traditional indication is used in combination with a scientific statement/claim relating to the mechanism of action of the ingredients, the combined claims must not imply clinical efficacy unless supported by scientific evidence. Indications and claims are discussed in more detail in [4.1 Differences between claims and indications](#_Indications_and_claims).

***Independent written histories***

When supporting evidence includes independent written histories of use in the classical or traditional literature (such as in relation to oral evidence or testimonials), the significance and clarity of references to any health benefit should be assessed by whether the:

* traditional paradigm is defined
* ingredient(s)/medicine is/are fully characterised (e.g.,. chemically, biologically)
* preparation is described
* dose and dosing details are documented
* route of administration is specified
* target population is defined
* traditional indication is described

***Evidence sources in languages other than English***

Evidence in a language other than English can be used, if the evidence package includes:

* copy of the relevant pages in the original language
* verified English translation of the relevant pages (a verified translation is one that is accompanied by a signed statement from an accredited translator, fluent in both languages, verifying that the translation is true and complete)

***Oral evidence sources***

If the traditional indication is from an oral culture, video footage (stored in a digital format, not on film) may be appropriate. To be regarded as high quality, oral evidence must be corroborated from at least two separate sources in different locations.

### Scientific evidence

Scientific evidence refers to quantifiable data and usually includes reports of clinical trials in humans; human epidemiological studies; animal studies; and other cellular or pharmacological studies. Due to the quantifiable nature of scientific evidence, scientific indications can imply clinical efficacy for health outcomes where the medicine’s efficacy is supported by such data.

#### Scientific evidence sources

Evidence types that may be included in the evidence package of listed medicines with scientific indications can be derived from sources such as:

* A systematic review
* A randomised controlled trial (RCT)
* A pseudo-randomised controlled trial (alternate allocation or some other method)
* A comparative study with concurrent controls
* A comparative study without concurrent controls
* Case series with either post-test or pre-test/post-test outcomes
* A review article

Refer to the [NHMRC levels of evidence and grades for recommendations for developers of guidelines](https://www.nhmrc.gov.au/sites/default/files/images/NHMRC%20Levels%20and%20Grades%20(2009).pdf)[[2]](#footnote-2) for definitions and more detailed discussion on types of evidence sources.

|  |  |
| --- | --- |
| Information | **Note: Non-clinical studies**  Non-clinical studies, such as animal or *in vitro* studies, **on their own** are not considered sufficient evidence to demonstrate the efficacy of a listed medicine with a scientific indication. The scientific uncertainties involved in extrapolating human health benefits from non-human data limit their usefulness. However, you may use non-clinical studies to support any discussion on biological plausibility or provide additional weight to a proposed indication to support efficacy claims when limited clinical studies are available. |

#### Other sources of scientific evidence

***Abstracts of scientific papers***

Abstracts generally do not give sufficient details as to how the research was conducted or the data were analysed to allow objective evaluation of the quality of the research data or the conclusions drawn by the study authors. Abstracts alone are not sufficient to demonstrate efficacy of a listed medicine with a scientific indication.

***Unpublished studies***

Unpublished studies or proprietary research can contribute to an evidence package for a scientific indication for a listed medicine if they are relevant and have been reviewed by at least two independent reviewers. To facilitate an accurate interpretation of methodological quality, any original research must be appropriately documented[[3]](#footnote-3).

|  |  |
| --- | --- |
| Information | **Note:** Requirements for independent reviewers to assess unpublished materials   * Independent reviewers should have relevant expertise and experience in the subject area under review. * If they cannot be objective and judge the study impartially due to direct or perceived conflicts of interest, they should NOT accept the study for review. * Conflicts of interest may arise if reviewers have professional or personal or financial affiliations with for example, author(s) and academic institution(s). |

***Internationally recognised monographs or pharmacopoeias***

High-quality and credible texts such as internationally recognised pharmacopoeias or monographs maintained by other international regulatory bodies or evidence-based reference texts may be appropriate to support the efficacy of listed medicines with non-specific indications (refer to 4.3 [Level of indications](#_Level_of_indications) for information on how indications are categorised into non-specific and specific).

These texts can also provide additional support for the efficacy of listed medicines with specific indications but this is only in addition to high level evidence. These texts cannot be used in isolation to support the efficacy a listed medicine with specific indications. Where possible, the relevant studies included in the monograph should be sourced and assessed for quality and relevance to the medicine’s indication.

## Literature searches

The following guidance is provided as a tool to assist sponsors find evidence that is high quality and relevant to a medicine. If further assistance is needed, we recommend engaging a specialist librarian to conduct a high-quality search to enable the collation of a strong evidence package.

A literature search is the first step in compiling a literature-based evidence package. The document [Literature-based submissions for listed medicines and registered complementary medicines](https://www.tga.gov.au/resource/literature-based-submissions-listed-medicines-and-registered-complementary-medicines) provides guidance on the scope of a literature search in the context of listed and registered complementary medicines. This section supplements that guidance document.

A well-constructed literature search identifies the general body of evidence related to a research question. There is no single search strategy that can be applied in all cases. For example, the design of a search strategy will be different if you are answering a research question related to a particular ingredient (e.g.,. ‘Does oral consumption of garlic reduce symptoms of the common cold?’) versus ingredients for a particular therapeutic use (e.g.,. ‘What ingredients are associated with reducing symptoms of the common cold?’).

Full details of the search methodology used to obtain evidence sources should be provided in an evidence package, including a clear explanation and justification for using it.

|  |  |
| --- | --- |
| Information | **Note: Search strategies**  The information in this section provides guidance on best practice standards for conducting literature searches. However, the TGA does not require sponsors to undertake a particular search strategy for listed medicines. |

### When a literature search can be conducted

A literature search can be undertaken at any of the stages of a product lifecycle, for example:

* at product development
* when product changes are made, e.g.,. change in formulation, addition of new indications
* periodically to ensure that the evidence package remains current

Note that the search parameters used in a literature search (e.g.,. dose, dosage form) may be affected by whether the product formulation is in development or already established.

### Types of literature searches

Literature searches can be **systematic** or **non-systematic**. The type of search used will affect the type of evidence retrieved and ultimately, the type of indications that can be used on a medicine. The evidence required to demonstrate the efficacy of listed medicines with different types of indications is described later in this document.

#### Systematic literature searches

[Literature-based submissions for listed medicines and registered complementary medicines](https://www.tga.gov.au/resource/literature-based-submissions-listed-medicines-and-registered-complementary-medicines) on the TGA website includes guidance on conducting a [systematic literature search to be included as part of a literature based submission](https://www.tga.gov.au/resource/literature-based-submissions-listed-medicines-and-registered-complementary-medicines). The [Cochrane Handbook of Systematic Reviews of Interventions](https://training.cochrane.org/handbook) provides detailed guidance on best-practice standards.

Systematic literature searches involve searching a comprehensive electronic bibliographic database such as:

* **MEDLINE** - a bibliographic database of all health-related publications in journals indexed by the United States National Library of Medicine.
* **EMBASE** - a biomedical and pharmacological bibliographic database specifically developed to assist finding information to comply with the regulatory requirements of a drug.
* **Web of Science** - a multi-disciplinary tool which provides website access to multiple proprietary bibliographic databases.
* The **Cochrane library** - a collection of health-related databases provided by Cochrane and other organisations, with Cochrane Reviews at its core.
* **BIOSIS** - a bibliographic database of life sciences and biomedical sciences literature, including pre-clinical and experimental research.
* **Scopus** - a multi-disciplinary bibliographic database covering journals, trade journals and books.
* **CABI Databases**:
  + *Global Health* (provides access to all the world’s relevant public health research and practice)
  + *CAB Abstracts* (a bibliographic database focused on life sciences literature)
* **AGRICOLA** - a database of agricultural literature indexed by the US National Agricultural Library of the US Department of Agriculture.
* **Food Science and Technology Abstracts** – a multi-disciplinary database focusing on food and health science.
* **AMED** - Allied and Complementary Medicine Database run by the British Library with specific information on complementary medicines not found elsewhere.

Access to MEDLINE is through the [PubMed](https://pubmed.ncbi.nlm.nih.gov/help/) search facility and there is a [learning tab](https://pubmed.ncbi.nlm.nih.gov/help/) which provides search instructions, tutorials and FAQs. MEDLINE/PubMed provides abstracts (summaries) and citations for the journal articles listed, and often links to full-text articles online.

|  |  |
| --- | --- |
| Information | **Note:**   * **General search engines** (for example: Google) are not considered appropriate databases for conducting a literature search. * **Journal abstracts or summaries** are not sufficient on their own to establish the efficacy of your medicine. You should access the full text in order to determine if it is high quality and relevant to your medicine. |

In addition to the use of bibliographic databases, ‘manual searching’ may be used to identify potential publications. The process of manual searching involves a targeted exploration of specific journals or other sources. This may include searching past issues of a peer-reviewed journal which is particularly topical to the research question but may not be listed on the selected databases. Alternatively, websites which are known to list published research on the chosen topic may be searched to identify any possible ‘missed’ publications.

***Determining the review question***

Defining a clinical question in terms of the specific therapeutic use for a medicine will help find relevant evidence in the literature.

The‘PICO Model’ is a format that can be used to help define the review question according to the following critical elements:

* **Population**: what are the characteristics of the target population, for example: persons with a specific condition or a general population.
* **Intervention**: what is the intervention under consideration for this target population, for example: a whole medicine or an individual ingredient.
* **Comparison** (if known): what is the alternative to the intervention, for example: a direct comparator or a placebo or no intervention.
* **Outcome:** what are the relevant outcomes, for example: specific outcome measurements or general health improvement.

**Example**:

**PICO model**

* Research Question: ‘Is Echinacea purpurea better than placebo at reducing symptoms of the common cold in adults?’
* Population or Problem: Adults experiencing mild to moderate symptoms of the common cold
* Intervention: Echinacea purpurea
* Comparison (if known): Placebo or no intervention
* Outcomes: Reduction in the severity of common cold symptom.

***Planning the search***

Once the research question has been defined, the next step is deciding on the search protocol. The search protocol includes:

* the research question
* a list of the databases and other sources used during literature searches to identify relevant studies
* the search methodology which is the keywords and criteria used to search a database

Using appropriate search terms is vital to ensure important publications are not missed. Familiarity with the field of study is necessary for this step as search terms should always include related synonyms, e.g.,. ‘complementary medicine’, ‘complementary therapies’, ‘alternative medicine’, ‘alternative therapies’, ‘integrative medicine’, ‘natural medicine’, ‘herbal medicine’, ‘holistic health’ and ‘holistic medicine’ may all be used for a complementary medicine literature review topic.

The searches should extend retrospectively for at least 10 years from the present day. Searches should not be limited to English. In particular, non-English language literature will need to be considered where there has been significant scientific work or if the medicine is largely based on a tradition where English is not the primary language of communication, e.g.,. Traditional Chinese Medicine. Every effort should be made to obtain translations of key references and the help of a specialist librarian may be useful when searching non-English databases.

***Inclusion and exclusion criteria***

Inclusion and exclusion criteria need to be established in the search protocol to determine which publications to include or exclude. These criteria need to be closely linked to the research question in the search protocol and may be based on:

* study design e.g.,. randomised or controlled trials only
* participants e.g.,. individuals who have experienced the symptom for a period longer than six months
* the intervention e.g.,. Chinese herbal medicine rather than broader herbal medicine
* language e.g.,. studies in English
* types of control e.g.,. intervention group and control group
* types of outcomes

As a first step, publications with data should be chosen to be included rather than commentary or other reviews. However, the latter may be useful for identifying additional articles for inclusion in the final evidence package.

The systematic and manual search of the literature should be documented such that a reader can understand the logic behind the search methodology. The [Literature-based submissions for listed medicines and registered complementary medicines](https://www.tga.gov.au/sites/default/files/literature-based_submissions_for_listed_medicines_and_registered_complementary_medicines_0.pdf) provides some guidance on how this can be achieved. The search terms and databases used and the numbers of references retrieved should be documented in your evidence package.

***How to incorporate critical elements in the search***

A literature search should include the following critical elements, where appropriate:


* health benefit
* active ingredient/formulation
* method of preparation of active ingredient
* dose
* dosage form
* route of administration
* frequency and duration of use
* population

***Controlled vocabulary and search strategies***

When possible, the terms of the PICO and the critical elements listed above should be translated into the controlled vocabulary of the database (list of standardised subject heading used by catalogues and database indexers to describe what a publication is about). Use subject headings, keywords, free text words, synonyms and truncation (wildcard) searching when necessary.

* Use **AND** to combine terms and narrow a search e.g.,. Searching ‘echinacea AND common cold’ will only retrieve results that contain both echinacea and common cold, which limits the results only to those papers -refer to Figure 3 below.
* Use **OR** to expand a search using synonyms e.g.,. Searching ‘echinacea OR purple coneflower will include papers that include any of those terms. OR always means MORE - refer to Figure 3 below.
* Apply **Limits** for publication type, year, age groups or other factors e.g.,. Limit to age group ‘Aged, 65 and over’; Limit to publication years ‘2010-2020;’ Limit to publication type ‘randomised controlled trial’. Any Limits you use need to be justified and reported in your evidence package.

**Boolean Search** uses a combination of keywords and Boolean operators (**AND**, **OR** and **NOT**) to organise and filter through searches. The ‘**NOT**’ operator is not generally recommended to be used in systematic searches as it has the potential to inadvertently exclude relevant articles. **Figure 3** shows the difference between ‘**AND**’ and ‘**OR**’ Boolean operators.

Figure : the difference between "AND" and "OR" Boolean operators

Each bibliographic database will also use their own search syntax, which will include various headings and categories, for example: MEDLINE uses [Medical Subject Headings](https://www.nlm.nih.gov/mesh/meshhome.html) (MeSH). The various MeSH can be browsed on the [US National Library of Medicine website](https://meshb.nlm.nih.gov/search).

A literature search can (and should) use free-text terminology as well as the relevant search syntax for the database, for example: For the search above, the MeSH for *Echinacea pupurea* is ‘echinacea’ and the MeSH for common cold is ‘common cold’.

When running a query in PubMed, use the [tiab] field code after each free text term. This will restrict the query to search in the title or abstract of the articles. By using both MeSH and tiab terms, you will increase the likelihood of finding all relevant articles.

It is also recommended to use synonyms to expand search results and ensure that they are comprehensive and relevant – this may include the inclusion of common names or Latin binomials for herbal medicine ingredients, or various synonyms for the condition being searched. This may also include using the term captured by the MeSH in free-text form anywhere in the title or abstract (e.g.,. [tiab]). The use of wildcards (e.g.,. \* in the example below) can ensure that *any* term will be included in your search.

An example of a MEDLINE search string for the simple search of echinacea in common cold is provided in the text box below. Note that each PICO category is defined in a search line before these lines are combined.

**Example:**

**MEDLINE search string**

1. "echinacea"[MeSH] OR “purple coneflower\*” OR “coneflower, purple” OR “coneflowers, purple”
2. common cold [MeSH] OR cold\* OR coryza OR coryzal OR catarrh\*
3. 1 AND 2

***Filtering search results***

If a substantial number of results are received (hits) while searching a database, the search can be refined by reducing the date range to the last 5-10 years. The justification for refining the date range should be included in your evidence package.

A search for evidence may retrieve several different types of evidence from a variety of different sources of literature. Review of the literature to produce a body of high-quality evidence that is relevant to the indication or medicine is known as ‘filtering’. However, care should be taken when applying filters as evidence may be inadvertently lost.

***Documenting the search methodology and results***

The search process for each database should be documented, including:

* all search terms and variations
* the date searches were carried out
* how many results were retrieved for each search
* the final number of results that used for the first pass
* all references found, even those that may be discarded later because they are irrelevant or poor quality and/or which do not support a relevant therapeutic use, to show that a balance of evidence approach has been considered
* how many records were duplicates

Further information on how to assess the evidence identified in a literature search refer to [3. How to assess evidence](#_How_to_assess).

An example of a well-documented search methodology and results is provided below:

**Example: Search protocol**

Aim: The literature search was structured to identify clinical studies on the efficacy and safety of Echinacea for the common cold.  
Database searched: PubMed  
Date searched: 28 April 2021  
Inclusion criteria:

* study using Echinacea
* clinical trials (any)
* systematic reviews
* safety or tolerability and/or efficacy in the common cold
* human study
* adults 19+ years

Exclusion criteria:

* Duplicate
* Echinacea use in different indications
* detail or design not sufficient to assess outcome/study quality
* conference abstracts
* not a pivotal source of evidence
* animal studies
* age group 0-18 years

**Example: Search protocol and results**

|  |  |  |
| --- | --- | --- |
| Search number | Query | Results |
| #1 | "echinacea"[MeSH Terms] | 800 |
| #2 | echinacea | 1,313 |
| #3 | "purple coneflower\*" | 66 |
| #4 | "coneflower, purple" OR "coneflowers, purple" | 1,313 |
| #5 | #1 OR #2 OR #3 OR #4 | 1,320 |
| #6 | common cold[MeSH Terms] | 4,271 |
| #7 | cold\* | 177,945 |
| #8 | coryza OR coryzal | 14,831 |
| #9 | catarrh\* | 7,441 |
| #10 | #6 OR #7 OR #8 OR #9 | 185,519 |
| #11 | #5 AND #10 | 195 |
| #12 | #5 AND #10 Filters: Adult: 19+ years | 50 |

#### Non-systematic literature searches

A non-systematic literature search is an informative search of the literature on a topic and takes an in-depth (but not systematic) approach to a specific research question. Generally, our preference is for a systematic literature search to be conducted in the first instance. However, a systematic search of scientific literature may not be the most effective way of retrieving evidence in all circumstances e.g.,:

* indications based on evidence of traditional use, where a search of traditional literature would be more effective
* some non-specific indications relating to health maintenance, for example: ‘Maintain general health and wellbeing’, for which a systematic literature search may not retrieve many relevant evidence sources

In these circumstances, it may be reasonable to justify using a non-systematic literature search. A non-systematic literature search may identify some, but not all, publications that address a particular issue. There are some shortcomings to conducting a non-systematic literature search e.g.,:

* the lack of a structured search strategy which is theoretically not reproducible
* limitations on the number of resources that can be searched
* an increased chance of selection bias

Evidence for a non-systematic literature search can be sourced from databases and print sources, such as:

* pharmacopoeias
* current and/or classical references in the specific field under review, for example: herbal or homoeopathic pharmacopoeias or materia medica
* standard works on the ethnobotany, or use of medicinal plants in a geographic area
* databases of biological literature, for example: BIOSIS or CAB Abstracts

It is good practice to document the details of a non-systematic literature search in the evidence package, including:

* where and how the evidence was sourced
* full bibliographic citation/s
* details of where and how terminology was established
* search methodology used
* why a non-systematic literature search was used instead of a systematic search
* why a non-systematic literature search is appropriate for the relevant indications

[Appendix 3](#_Appendix_3:_Example) provides an example of evidence package where a search strategy (including systematic and non-systematic searches) has been documented.

# How to assess evidence

Once evidence sources have been identified from a literature search, each source should be assessed individually to determine if it is relevant to the medicine and of high quality.

## How to assess if evidence is relevant

There are many parameters of a medicine design that impact its efficacy. It is important that the parameters of the medicine are relevant to the evidence sourced in order to show the TGA that the data in the source can be extrapolated to the sponsor’s medicine. Examples of key parameters include:

* health benefit/therapeutic use/indication
* active ingredient
* formulation
* method of preparation of the active ingredient
* dose
* dosage form
* route of administration
* frequency and duration of use
* population

If a medicine is designed based on the sourced evidence, the medicine design should match the key parameters in the evidence source. Conversely, if the medicine was designed prior to sourcing evidence, the key parameters in the evidence source should be comparable to that of the medicine.

Most literature-based submissions are based on publicly available literature that does not specifically investigate a unique medicine design. Establishing relevance helps answer the question: ‘On what basis can it be concluded that the medicine will result in this therapeutic effect?’

The evidence package should demonstrate how each of the key parameters (such as those listed above) in the evidence source compares to the medicine design so that the therapeutic effect described in the source can be extrapolated to the medicine and thus support the efficacy of the medicine.

|  |  |
| --- | --- |
| Information | **Note:**  Ideally, all the parameters in the evidence sources should match the parameters of the medicine. There may be cases where one or more of the parameters in the source is not identical to the medicine but may be similar or not specified. These sources may still form part of your evidence package, depending on the other evidence sources included and the accompanyingjustification of relevance provided. For further information refer to [‘3. How to collate and present evidence’](#_How_to_present). |

### Health benefit stated in literature

The health benefit described in the evidence source should match the therapeutic use described by the permitted indication/s selected for the medicine. When transcribing these permitted indications onto the medicine label and other advertising, the extent, nature, or prominence of the effects observed should not be exaggerated or suggest greater certainty than what was demonstrated in the evidence source. Also note that a medicine cannot advertise indications that are not included in the ARTG for the medicine.

[Appendix 2](#_Case_study_1) provides a case study ([case study 1](#_Case_study_1)) that demonstrates an incorrect extrapolation of the health benefit described in the evidence source to a hypothetical medicine.

### Active ingredient

The evidence source should relate to the whole medicine or include the same active constituent/s and be similar or comparable to the medicine in terms of:

* dose
* dosage form
* dosage regimen (including duration and frequency of administration)
* route of administration

[Appendix 2](#_Appendix_2:_Case_1) provides case studies demonstrating:

* where the active ingredient in the evidence source is not equivalent to the medicine in terms of dose ([case studies 2](#_Case_study_2) and [3](#_Case_study_3)), method of preparation ([case studies 4](#_Case_study_4) and [5](#_Case_study_5)) and [dosage form](#Case_study_6) ([case study 6](#_Case_study:_Dosage))
* a discrepancy in the active ingredient used in the evidence source but with an appropriate justification for the inclusion of the source in an evidence package ([case study 13](#_Case_study_16))

#### Active ingredients from evidence of traditional use

When the medicine contains a herb or herbal substance, the species (and subspecies where applicable), plant part and route of administration of the medicine should be comparable to that described in the evidence source. The method of preparation and processing, the equivalent dry weight and the dose of active component described in the evidence source should also be comparable to that in the medicine.

Traditional methods of preparation include:

* the use of a whole organism or specific parts e.g.,. leaf, root, fruiting body etc.
* fresh, dried, or preserved with alcohol, honey or sugar
* extracts produced by the application of pressure to the source material
* aqueous extracts such as infusions, decoctions and syrups
* ethanol-based extracts such as tinctures
* glycerine-based extracts
* vinegar-based extracts
* oil, grease or fat-based infusions
* beeswax salves and ointments

Other methods of preparation may be considered traditional if supported by an appropriate reference describing the use of the method within the traditional medicine paradigm.

|  |  |
| --- | --- |
| Information | **Note: Herbal ingredients**  For listed medicines with herbal ingredients, additional information can be found in the Guidance on equivalence of herbal extracts in complementary medicine. |

Medicinal preparations described in early pharmacopoeias, materia medicaand other traditional references may pre-date modern analytical techniques. These are unlikely to provide a comprehensive and satisfactory specification (for the characterisation and establishment of the quality of the ingredient or medicine). In such situations, the active ingredients and method of preparation should be comparable to that described in the traditional literature. Where there are differences in parameters, such as the dosage or method of preparation, justifications (substantiated by evidence) should be included in the evidence package to explain why the discrepancies have no impact on the extrapolation of the traditional evidence to your medicine.

In general, active ingredients may be considered as sufficiently comparable if there are no relevant differences in the method of preparation (such that comparable outputs are yielded) and if the medicine has the same intended purpose, dosage and the same route of administration. This may include traditional medicines in which the indication, dosage and administration are based on traditional knowledge, the dosage forms have been modified to modern dosage forms (e.g.,. capsules or tablets) but the outputs have been demonstrated to be comparable.

***Modification of traditional formulations***

Modification to the traditional formulations in well-established and well-documented traditional medicine systems (such as Traditional Chinese Medicine and Ayurvedic medicine) should ensure that the traditional method of preparation, traditional formulation principles and dosage for the therapy are retained in the medicine design in order for the traditional indication to be used.

The overall medicine formulation should reflect the traditional principles of ingredient combinations or substitution of herbal species. If the medicine uses traditional ingredients or formulations which have been significantly altered in their constituent profile from the traditional evidence source, a justification and/or additional information should be provided in the evidence package.

Non-traditional methods of preparation of otherwise traditional materials, including the use of non-traditional solvents and/or extraction ratios, can change the chemical profile of the preparation. Such changes may affect the efficacy (and safety) of the medicine. Medicines that have been altered significantly in their constituent profile from the traditional medicine on which the indication is based will require justification supported by relevant information to substantiate the extrapolation of the therapeutic effects described in the evidence source to the listed medicine.

#### Active ingredients from scientific evidence

The active ingredient should be well characterised in the evidence source. Preparations used in the source should contain the same ingredient preparation and dosage form as the medicine.

For evidence sources related to a herb or herbal substance, the species (and subspecies if applicable), plant part, method of preparation and processing, the equivalent dry weight and the dose of active component described or used in the source should be consistent with that of the herb or herbal substance in the medicine. If the processing used to prepare a particular herbal product is different to that used in the literature, evidence that the chemical profile of the resulting active ingredient/s is not substantially different from the active ingredient in the literature will need to be provided. Unfortunately, many trials inadequately describe or characterise the composition of the herbal treatment. Even when the herbal ingredient is standardised to known active therapeutic components or marker compounds, there can be variation in the concentration of other components in the herbal extract that may result in different pharmacological activity *in vivo*. This should be documented in the evidence package accompanied with a justification for why the differences have no impact on the extrapolation of the data in the evidence source to your medicine.

Other characteristics of medicines used in clinical trials may also impact on their relevance to a proposed indication e.g.,. an evidence source with a dosage form designed for slow release of an active ingredient may not be relevant to medicines with indications that imply the health outcomes are achieved rapidly (e.g.,.‘for the rapid relief of pain / fast acting formula to relieve pain’).

### Frequency and duration of use

The way that an ingredient or formulation is administered to produce the observed health benefit in the evidence source should be comparable to that of the medicine.

For a clinical study to be relevant, the study duration needs to be of an appropriate time to validate the health benefit described by the indication. The appropriate study duration depends on the nature of the health benefit. If referring to a short-term benefit such as acute pain relief, a clinical study of only several hours duration may be adequate. On the other hand, where long-term benefits are implied, clinical studies should be of sufficient duration to establish a sustained response that is likely to be meaningful. Examples of such long-term benefits include: maintenance of health; risk reduction; or favourable modulation of body weight, as the body’s homeostatic processes may reduce early gains. This is of particular importance for medicines designed for weight loss. This is explained in further detail in [4.4.4 Weight loss indications](#_Weight_loss_indications)

[Appendix 2](#_Appendix_2:_Case_1) provides a case study example of the study duration not being sufficiently applicable to the indication of a hypothetical medicine ([case study 15](#_Case_study:_Study)).

Evidence of traditional use may not refer explicitly to a ‘study duration’. However, traditional evidence sources may have a context of use that relates to a particular duration of use for the medicine or ingredient, and this should be comparable to the medicine.

### Target Population

The target population for the medicine should be consistent with the population described in the evidence source. It is important to note that, in general, listed medicines are intended for use by healthy individuals.

The general population is categorised as the following:

* male and female participants
* generally healthy
* aged 18–65 years
* socio-culturally similar to the Australian population

Where a target population is not specifically mentioned for a medicine (e.g.,. in the indication, directions for use etc), it is assumed that the target population of the medicine is the above general population.

The relevance of evidence sources that target a population with non-serious disorders or in situations where a continuum of health and disease exists, such as individuals in early disease states, should be considered carefully. In general, evidence sources with populations that have serious diseases, conditions or ailments may not be extrapolated to a healthy population and may not be considered relevant to a listed medicine indicated for the generally healthy population. However, in cases where there is data to suggest that the pathophysiology of the disease does not change the way the active ingredient works in the milder form of disease, compared to the more serious form of disease, the relevance of these evidence sources may be justified. Extrapolation of results obtained from subjects outside the target population of the medicine should be appropriately justified.

When an indication is directed towards a specific subgroup of the population (e.g.,. the elderly, pregnant women) it needs to be supported by data derived from the same subgroup of the population. Similarly, evidence sources from a specific subgroup cannot be extrapolated to the general population, unless adequately justified e.g.,. data from clinical studies that only use females in the treatment group may not be generalisable to generally healthy adults (depending on the objectives of the study). **Table 1** provides some examples of the characteristics of study populations that are relevant to the target population.


Table : Study populations

|  |  |
| --- | --- |
| Indication | Relevant population |
| Helps increase weight loss when used in conjunction with a calorie or kilojoule-controlled diet and physical activity or exercise | Male and female participants aged 18-65 years; generally healthy population with BMI 25-30 kg/m2 socio-culturally similar to the Australian population. |
| Relieve pain | Male and female participants aged 18-65 years; generally healthy population with a range of painful (non-serious) conditions. |
| Relieves cough in children | Male and female participants aged 2-12 years; generally healthy population with cough associated with a range of (non-serious) conditions. |
| Maintains bone strength | Male and female participants aged 18-65 years; generally healthy population; dietary and lifestyle pattern similar to the Australian population. |

The case studies [8](#_Case_study_8) and [9](#_Case_study_9) in [Appendix 2](#_Appendix_2:_Case_1) show examples of evidence sources considered relevant to a medicine. Case studies [10](#_Case_study_11) and [11](#_Case_study_12) are examples of evidence sources not considered relevant to a medicine.

The decision tree in **Figure 4** can be used as a tool to help determine if the evidence source is relevant to the medicine and when additional justification of relevance is required in your evidence package.

Figure : Is your evidence source relevant to your medicine and indication?



## How to assess the quality of evidence

Each source of evidence should be assessed to determine if it is of sufficient quality. Quality in this context means how certain or confident we can be that the estimates of the therapeutic effect in an evidence source is correct. Depending on the evidence sources, some of the factors that may increase or decrease our confidence in the information presented include:

* risk of bias
* precision of the effect estimates
* consistency of the individual study results
* how directly the evidence answers the question of interest
* risk of publication or reporting bias

When we discuss the hierarchy of scientific evidence, we are referring to the type of evidence/study design and how much the reported results may be impacted by bias. Scientific evidence sources can be categorised into a hierarchy based on how much the source is impacted by bias. In contrast, traditional evidence sources do not have a hierarchy based on bias.

Certain sources of scientific evidence provide a lower risk of bias than others due to their design, methodology or level of review. When designed and implemented appropriately, double blinded randomised controlled trials (RCT) and systematic reviews of multiple randomised controlled trials are the most likely to achieve low bias and high precision when studying treatment effects (high quality). Conversely, if an RCT is not appropriately designed and implemented, the results generated may not be robust and reliable (poor quality).

**Table 2** provides a hierarchy of scientific evidence types. The evidence types under Category A are generally better at controlling bias and accordingly, are attributed the most weight in an assessment of the body of evidence. Category C evidence types can be more affected by bias and therefore are usually attributed the least weight.

Table : Hierarchy of scientific evidence sources based on risk of bias

|  |  |  |
| --- | --- | --- |
| Scientific evidence | | |
| **Category A** | **Category B** | **Category C** | |
| Double blind randomised controlled trials (including cross-over trials) | Observational studies e.g.,. cohort and case-controlled studies | Non-systematic, generalised reviews – including databases | |
| Systematic reviews | Comparative studies (non-control) | Publicised international regulatory authority articles | |
| Evidence-based reference texts - ***scientific*** | |
| Scientific monographs | |

When reviewing evidence from any of the categories in Table 2 to determine whether to include in your evidence package, you should consider the limitations commonly associated with each evidence type. Depending on your chosen indication, cohort and case-control studies may not be enough to substantiate the indication (i.e. efficacy) due to the higher risk of bias associated with these types of studies. In these situations, the studies may be included in your evidence package to be critically appraised in conjunction with other evidence sources.

While double blinded randomised controlled trials and systematic reviews of multiple randomised clinical trials are usually associated with low bias and high precision, they are not always available or feasible. Acknowledging this, the TGA allows other study types and a range of other sources of evidence to be submitted as potential support for the claimed efficacy of a medicine. The limitations of these other sources need to be considered e.g.,. case-control studies and cohort studies may not be a practical means of providing evidence for some indications and are limited in their ability to produce unbiased and unambiguous data regarding the true efficacy of a medicine. They can, however, provide valuable supportive data related to the likely efficacy of a medicine for the general population.

Ultimately, it is up to you, as the sponsor, to demonstrate in your evidence package why the evidence types are appropriate for your particular medicine (and indication/s) and why the risks of bias in those evidence types have no impact on the overall conclusion on the medicine’s efficacy.

[Appendix 2](#_Appendix_2:_Case_1) includes case study examples ([case studies 8](#_Case_study_8) and [9](#_Case_study_9) demonstrating evidence sources that are relevant to a hypothetical medicine. [Case study 10](#_Case_study_11) provides an example of evidence sources that are not relevant to a hypothetical medicine and is not of sufficient quality.

### Assessing the quality of evidence of traditional use

Each evidence source must be considered on its own merit in relation to the medicine. An evidence source can only be considered legitimate if it establishes a tradition of use, is credible and relevant to the medicine and indication.

***Is the evidence of traditional use from a credible source?***

Evidence of traditional use for an indication needs to show that the medicine or the relevant ingredients in the medicine, have a significant and recognised history of use in the specified tradition for the specified health benefit.

To use a traditional indication, the medicine or ingredient must be an accepted part of a tradition of medicinal use within an established paradigm for over three generations (75 years). This will demonstrate a recognised history of use that underpins the use of the medicine.

Refer to [Appendix 2](#_Appendix_2:_Case_1) for [case study 11](#_Case_study_12) that shows an example of a traditional evidence source that is not of sufficient quality.

### Assessing the quality of scientific evidence

Clinical research should be conducted in a manner that yields meaningful and reproducible results. The design, implementation, results, and reporting of each piece of research are important factors that determine how much confidence we may have in the data generated and the author’s conclusions relied upon.

The [Grading of Recommendations Assessment, Development and Evaluation](https://www.gradeworkinggroup.org/) approach to assessing the certainty of a body of evidence is considered best practice by many international organisations. It provides a structured way to consider the level of confidence that can be placed in an evidence source and may be a useful tool to help assess which sources to include in your evidence package. It may also help determine how much weight to place on certain evidence sources during a critical appraisal of the body of evidence.

The rest of this section outlines important factors for assessing the quality of scientific evidence that was identified in the literature search. As there is no single set protocol for how to conduct research, it is important to critically appraise evidence sources in terms of these factors. If these factors are not adequately described in the evidence source, and therefore you cannot determine whether bias has been adequately controlled, then you should carefully consider whether to include it in your evidence package. If you still decide to include that evidence source in your evidence package, then it should be accompanied by a discussion of the impacts of the potential bias on the data in the evidence source in the context of the body of evidence included in your package.

#### Evaluating the study design

Evaluation of study design is an essential part of assessing the quality of scientific evidence. The below sections describe important components of study design that, when appropriately considered and applied, contribute to the quality of the evidence source.

Ideally, the evidence source included in your evidence package should be high quality in terms of the factors outlined in the following section. There may be instances where the evidence source does not address all factors. Where information is missing, it is up to the sponsor to rationalise the potential impacts on the conclusions about the efficacy of the medicine.

|  |  |
| --- | --- |
| Information | **Note:** Not all evidence sources will have applied or discussed all the factors described below. If a sponsor chooses to include such evidence sources in the evidence package, it is the sponsor’s responsibility to justify ***how*** the limitations in the evidence sources do not impact on the conclusions about the body of evidence (included in the evidence package) and the efficacy of the medicine. |

#### Study design and methods

Clinical trials should have clearly documented aims and methods. Study design (including the presence or absence of randomisation and blinding), measurement tools (and their validation) and statistical methods should be clearly outlined. Inclusion and exclusion criteria and the baseline characteristics of study participants should be described. The baseline distribution of potential confounders should be shown and any potential confounding factors should be considered, and accounted for, during the analysis. In addition, the limitations of the study design and/or the methodology chosen, and their potential implications, should be discussed by the authors.

The randomisation method and other critical study design parameters should be described and meet contemporary standards to allow an assessment of whether any bias was introduced into the study.

#### Intervention and control groups (study trial arms)

Randomisation of participants to intervention (in the context of these guidelines, the group taking the listed medicine) and control arms of a trial helps reduce innate inter-group differences and potential bias. The method of randomisation should be clearly described. Baseline characteristics of treatment and control groups should always be documented to establish equivalence in key areas such as age, weight, diet, and other factors that may contribute to non-treatment differences in health benefit between groups.

Ideally, trials should be conducted under conditions where the only difference between groups is that one is exposed to the intervention (medicine) and the other is not. This is often achieved in controlled trials but is less likely to occur in cohort studies and case-control studies. In these methodologies, the presence of potential confounders and study biases may impact on study results and should be considered and accounted for in your analysis of the study. When confounders exist within a study, they lessen the study’s quality and the degree of confidence in the reported study outcomes.

#### Study outcomes: primary and secondary clinical outcomes

A primary outcome is the main health benefit being investigated in a clinical trial. A secondary outcome may be another outcome that is measured during a trial but may not be the main question the study is trying to address. Ideally the medicine’s indication will be included in the study as a primary outcome. However, inclusion of the indication as a secondary outcome may possibly be justified in some cases if, the study design adequately controls for bias and the observed result is shown to be statistically and clinically significant.

Evidence sources that only demonstrate a substance’s mechanism of action are not considered equivalent to the demonstration of a clinical outcome. However, such sources may be useful as part of the body of evidence to justify the biological plausibility of a clinical outcome e.g.,. a non-clinical study that shows *in vitro* inhibition of COX enzymes by green lipped mussel should not be used on its own to demonstrate that a medicine can relieve inflammation.

Some evidence sources may refer to a particular measurement method used to assess study outcomes e.g.,. visual analogue scales to subjectively assess pain, hunger etc. It is important that these methods are validated to ensure that the method is appropriate and accurate for its intended purpose and that the results can be reproduced. If the measurement method has been borrowed from another party, the original authors that developed and validated the method should be cited in the study. It is good practice to check the validation conducted by the original authors. If a measurement method has been appropriated from another party and has been modified, it is also good practice to check for signs that the modified method has been validated.

Where information about method validation is not reported in a study, the impact of this on the conclusions drawn from that study should be accounted for. Whether there is confidence in the measurement method to generate reliable and accurate results should be considered and documented for each evidence source included in the evidence package.

[Appendix 2](#_Appendix_2:_Case_1) provides a case study ([case study 1](#_Case_study:_Non-validated)4) demonstrating a clinical study where a measurement method was appropriated but not validated.

#### Statistical analysis

In general, the principles outlined in [Note for Guidance on Statistical Principles for Clinical Trials](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf) (ICH Topic E9) should be considered when assessing whether the statistical analysis of a clinical study has been conducted in a robust manner.

Even if a clinical study is well-conducted and sources of bias are limited, there is a possibility that the results arose purely by chance. Studies can use various statistical methods to minimise a ‘Type I error’ (also known as a false positive) where a conclusion has been made that there is a difference between two study interventions when no difference really exists. It is important to bear in mind that statistical significance does not provide information about the degree of health benefit produced or whether it is likely to be clinically meaningful and, as such, clinical significance should be considered in addition to statistical significance. For more about clinical significance, please see section [3.2.2.7 Clinical significance](#_Clinical_significance).

An evidence package should include an assessment of the results reported in each evidence source (taking into consideration all factors outlined in [3.2.2 Assessing the quality of scientific evidence](#_Assessing_the_quality)) and a discussion of why the conclusions drawn by the author/s (as a result of the statistical analysis conducted) can be relied upon.

##### Statistical significance (p-value)

Well-conducted clinical studies will usually report the degree of statistical significance (p-value) associated with the observed difference between treatments. The p-value indicates the probability that an observed effect is due to chance (that is, the probability of making a Type I error). Although there is no definitive p-value threshold, the lower the p-value the greater the likelihood that the effect observed is real. In practice and in general, a p-value of less than 0.05 indicates with acceptable certainty that an observed effect or health benefit is unlikely to be due to chance.

Things to consider relating to statistical significance and the p-value include whether:

* the statistical test used to derive the p-value is appropriate and reliable
* the p-value obtained for the primary outcome is less than 0.05
* all the actual p-values (not just p < 0.05) are reported

##### Statistical significance (confidence intervals)

Confidence intervals provide an alternative measure of statistical certainty. The confidence interval (CI) is the range of values within which there is a certain likelihood that the true value can be found. The confidence level is the probability that the CI contains the true difference. Well-conducted studies should usually report the 95% CI. This means that there is a 95% chance that repeated experiments would have outcomes that fall within the specified range.

The precision (or width) of the CI is also an important consideration. A narrow 95% CI is much more desirable than a wide 95% CI. A wide CI indicates a low level of confidence in what the true population effect is.

To demonstrate that there is indeed a difference between the treatment and control groups, the 95% CIs of the treatment and control groups should not overlap.

##### Factors affecting statistical significance of study outcomes

**Attrition rates** (dropout rates) are commonly high in clinical studies that evaluate health benefits that are modest and require long-term commitment. High attrition can introduce serious bias (attrition bias) into these studies because the reasons for non-completion vary across initially randomised groups. High attrition rates may also diminish the general applicability of the treatment to any population, as it is unclear which socio-demographic or other factors may be associated with dropout. The resulting data from a high attrition study should be interpreted with caution.

**An Intent-To-Treat** (ITT) analysis, in which outcomes of the original randomised groups are compared, provides a means of accounting for the effects of dropouts. In an ITT analysis, dropouts from the study are included in the analysis. When an ITT is performed, all efforts should be made to obtain outcome measurements from dropouts at the end of the study. In cases where this is not possible, baseline measurements of study parameters should be carried forward e.g.,. for a study outcome related to weight loss, body weight recorded at the beginning of treatment would be carried forward to the end of the study for dropouts. In this way, a treatment effect demonstrated in an ITT analysis underestimates the efficacy of the treatment but may be a good reflection of effectiveness under real world conditions[[4]](#footnote-4).When dropouts are not accounted for in the analysis of results, attrition bias (exclusion bias) may result.

**Number of participants** (power calculations): The power of a study is the probability of detecting an effect when the effect is truly there. Power is proportional to sample size i.e. the greater the sample size, the greater the power of the test. However, very little power is gained by increasing the sample size beyond a certain point. A power analysis is used to perform sample size calculations in order to determine how many subjects are required in a clinical study in order to detect a difference between treatment and control groups.

It is important that studies enrol sufficient numbers of participants to detect a significant and reliable treatment effect. The number of participants required to be reasonably certain of a reliable result needs to account for the degree of health benefit (effect size), the variability of individual results and the number of participants dropping out of the study (attrition rate). Therefore, a study may need to include larger numbers of participants to account for a high attrition rate and/or small effect size. Conversely, where an effect size is large, a study may only require a small number of participants to measure the effect reliably and accurately.

A sponsor is not expected to perform power calculations on behalf of study authors, but consideration should be given to: any limitations of the statistical analysis that the study authors have reported, including how the study was powered (and why this is appropriate); why a certain effect size was selected; number of dropouts; and how these factors impact on the reported study outcomes. If you choose to include an underpowered clinical study in your evidence package, you should include a justification for why you think the study outcomes can be relied upon to reflect the efficacy of your medicine in the context of the body of evidence included in your package.

Often high-quality clinical studies have been designed to ensure that the results generated are statistically robust. The authors would have considered the factors that are important to achieve the desired outcome, have designed the study accordingly and determined how they would conduct their statistical analysis prior to running the study (to reduce the risk of data dredging).

#### Tools for assessing risk of bias

The [National Health and Medical Research Council](https://www.nhmrc.gov.au/) has the following definitions for bias and risk of bias:

* **Bias** refers to factors that can systematically affect the observations and conclusions of the study, causing them to be different from the truth. Studies affected by bias can be inaccurate. for example: finding false positive or false negative effects or associations by over- or under-estimating the true effect. More often than not, it is difficult to tell from the study results whether bias is present, instead, we can assess the study design to gauge the risk of bias – see below.
* **Risk of bias** refers to the likelihood that the features of the study design or conduct of the study will give misleading results

There are a number of ways to [assess risk of bias for different studies](https://www.nhmrc.gov.au/guidelinesforguidelines/develop/assessing-risk-bias), with the most commonly employed tool for assessing risk of bias for randomised clinical trials being the [Cochrane Risk of Bias tool](https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials). Whether you choose to use these tools or not, a discussion of why you believe the evidence sources included in your evidence package have adequately controlled for bias should be included in your package.

|  |  |
| --- | --- |
| Information | **Note:** The following tools may assist assess the quality of the evidence source:   * **PRISMA /** [**AMSTAR**](https://amstar.ca/index.php) – developed to evaluate systematic reviews of randomised and non-randomised trials * [**CASP**](https://casp-uk.net/casp-tools-checklists/) – series of critical appraisal checklists designed for use with systematic reviews, RCTs, cohort studies, case control studies etc. * [**CEBM**](https://www.cebm.ox.ac.uk/resources/ebm-tools) – has a selection of tools to assist with critically appraising literature * [**CONSORT Statement**](http://www.consort-statement.org/) – provides the international standards for reporting randomised trials * [**EQUATOR Network**](https://www.equator-network.org/) – provides reporting guidelines for all main study types |

#### Clinical significance

Not all statistically significant differences are clinically significant. A statistically significant outcome only indicates that the difference observed or measured between two groups (i.e. treatment vs control) is unlikely to have occurred by chance. Whereas clinical significance is the practical importance of the treatment effect – whether it has a real, palpable, noticeable effect on a person’s daily life.

For listed medicines, this may be regarded as ‘a degree of health benefit that is meaningful to the consumer’. The number of participants required to detect a clinically significant difference between treatment and control groups depends on the type and level of health benefit, the standard deviation of the health effect, the significance level (p-value) and statistical power of the study and the type of hypothesis being tested.

Determining the clinical significance of health outcomes associated with listed medicines is particularly difficult for the following reasons:

* Listed medicines are self-selected by consumers from a wide variety of backgrounds, with varied expectations and variable educational and financial resources.
* The health outcomes provided by listed medicines may be modest, not readily apparent, and/or achieved over long periods of time.
* Healthy consumers may be satisfied with smaller gains in health than individuals with a pre-existing condition.

Therefore, it may not always be possible to determine clinical significance of evidence sources, but this concept should be considered when assessing the balance of evidence.

# How to use evidence

The following section provides information about indications and claims for listed medicines and how evidence can be used to demonstrate efficacy.

## Differences between claims and indications

|  |  |
| --- | --- |
| Information | **Note:**   * **Health benefit** refers to the beneficial effect of a medicine formulation or ingredient on health outcomes as described in an evidence source. * **Indication** is defined in the Act as the specific therapeutic use/s of a medicine. * **Claim** refers to a statement that does not describe a therapeutic use. Claims which imply therapeutic uses are assessed as indications. |

### Indications

Indications describe the specific therapeutic use/s of the medicine. Consistent with their low-risk status, listed medicines may only use low level indications included in the [Permissible Indications Determination](https://www.tga.gov.au/therapeutic-goods-determinations).

Low level indications may:

* refer to general health maintenance
* refer to health enhancement
* refer to the prevention of a dietary deficiency
* imply a benefit for a non-serious form of a disease or condition

Low level indications may NOT

* refer to or imply the prevention, cure or alleviation of any disease, ailment, defect or injury.

The [Permitted indications for listed medicines guidance](https://www.tga.gov.au/therapeutic-goods-determinations) provides information about permitted indications for listed medicines including: terminology; structure; use; and how to apply for new indications.

#### Permitted indication qualifiers

When entering a medicine in the ARTG via the Electronic Listing Facility (ELF), sponsors can select ‘indication qualifiers’ from drop down lists to make a permitted indication more detailed and align with the evidence they hold for the medicine. There are four different types of indication qualifiers available:

* traditional context (for traditional medicines only)
* time of use e.g.,. ‘after eating’
* population e.g.,. ‘in men’
* TCM pattern (for TCM medicines only)

For more information on indications qualifiers refer to the [Permitted indications for listed medicines guidance.](https://www.tga.gov.au/therapeutic-goods-determinations)

### Claims

In this guidance, a claim refers to a statement that does not describe a therapeutic use. Listed medicines may include claims or statements on their labels or other advertising in addition to permitted indications. Claims are not required to be included on the medicine’s ARTG entry, but a sponsor must still hold evidence to support these ‘claims’ (based on the sponsor certifications made under section 26A of the Act).

However, in some circumstances, a claim or statement may be considered to imply a therapeutic use. A therapeutic use may be implied where the message conveyed to the consumer suggests that the product is intended to influence, inhibit, or modify a physiological process. Where this is the case, a permitted indication of similar intent must be included in the ARTG entry and supported by evidence, for example: a medicine presented as a calcium supplement with a claim on the label stating, ‘*Calcium is an essential component of strong bones*’ will require evidence supporting the role of calcium for a related permitted indication such as ‘*Maintain/support bone strength*’ and the related permitted indication should be included in the medicine’s ARTG entry.

Refer to the [Permitted indications for listed medicines guidance](https://www.tga.gov.au/publication/permitted-indications-listed-medicines-guidance) for more information on claims.

## Types of indications

Listed medicine indications are classified as traditional or scientific indications based on the type of evidence used to demonstrate efficacy. Scientific indications are further categorised according to the level of specificity: non-specific or specific.

### Traditional indications

Traditional indications present factual statements of a health benefit relating to a historical record of use within a recognised paradigm outside modern conventional medicine e.g.,. Traditional Chinese Medicine, Aboriginal and Torres Strait Islander healing practices, Ayurvedic medicine, Western herbal medicine.

Traditional indications must be based on long-term use (more than three generations, that is, 75 years) within a specific paradigm. The traditional use should be extensively documented in internationally recognised evidence sources for traditional medicine use.

In practice, the language used in traditional medicine paradigms can make it difficult to determine if an indication is specific or non-specific. Therefore, the TGA’s focus for traditional indications is whether efficacy is supported by legitimate traditional sources of evidence rather than the specificity of the indication.

A traditional indication must include the traditional context of use (see [4.1.1 Permitted Indication qualifiers](#_Permitted_indication_qualifiers)) to clarify that the efficacy of the medicine carrying the indication is supported by a history of use within a specific traditional paradigm rather than based on quantitative scientific data. A medicine may include multiple traditional paradigms if the ingredient has been used within more than one traditional paradigm for the same indication e.g.,. ‘Ingredients in this medicine have been traditionally used in Ayurvedic and Chinese medicine for relieving symptoms of the common cold’.

|  |  |
| --- | --- |
| Information | **Note:** Under the [Therapeutic Goods Advertising Code](https://www.tga.gov.au/publication/therapeutic-goods-advertising-code), advertisements for listed medicines that include indications (or “one or more claims” as referred to in that document) based on evidence of a history of traditional use must:   * disclose the reliance on this traditional use * prominently display or communicate this disclosure in the advertisement |

When using a traditional indication, a sponsor should:

* select the traditional paradigm that supports the formulation of traditional medicine
* ensure the evidence supporting the efficacy is based on experiences or theories specific to the particular tradition, not on scientific clinical evidence
* ensure the indication has the same meaning and intent as specified in the evidence
* ensure the indication uses the same logic and terminology (may be accompanied by English terms on the medicine label) asthe evidence of use in the specified traditional paradigm

Traditional indications cannot:

* refer to anatomical, physiological or pharmacological effects that are not envisaged within the specified paradigm e.g.,. ‘raise haemoglobin levels’
* imply efficacy based on scientific evidence for the medicine e.g.,. ‘clinically tested’
* use specialist terminology that belongs to a different paradigm e.g.,. ‘damp heat’ is a term that is specific to the Traditional Chinese Medicine paradigm and would be inappropriate for an Ayurvedic medicine
* include qualifications that require scientific substantiation e.g.,. ‘assists to increase bone density by 10%’
* refer to conditions that cannot be diagnosed within the specified paradigm e.g.,. ‘Traditionally used in Chinese medicine to increase bone mineral density’ is inappropriate as increased bone mineral density cannot be monitored or determined without conventional medical intervention
* refer to the modulation of biomarker levels or weight loss

When choosing a traditional indication, the following questions should be considered:

* Are the terms used to describe the indication the same as those used in the evidence source of traditional use?
* If the terms are different from those in the evidence source of traditional use, can the change be justified?

Evidence sources of traditional use can be based on the medicine formulation or for an individual ingredient. If a traditional indication is linked to an individual ingredient in a medicine formulation, then that ingredient should be clearly linked to that indication on the medicine label.

In some instances, multiple sources of evidence of traditional use may be needed to support the efficacy of a listed medicine with a traditional ingredient or formulation. Together these sources should form a combined collective body of evidence that should be critically appraised in the evidence package.

If there is conflicting evidence between the history of traditional use and contemporary scientific evidence for the medicine, then it is advisable to include a statement to this effect in any labelling and advertising associated with the medicine, for example: ‘this traditional use is not supported by scientific evidence’. This will ensure that the advertised information relating to your medicine is truthful, valid, and not misleading.

#### Medicines from more than one traditional medicine paradigm

Many traditional medicine paradigms use similar ingredients. A listed medicine may contain multiple traditional ingredients that are supported by evidence of therapeutic use in different traditional paradigms e.g.,. a Traditional Chinese Medicine ingredient may be combined with an Ayurvedic ingredient but as the new formulation is neither a Traditional Chinese Medicine nor Ayurvedic medicine, the formulation, as a whole, cannot claim a history of use. Each traditional ingredient should be linked to a separate traditional indication that refers to the specific traditional paradigm of use.

However, when combining ingredients from traditional paradigms, sponsors should ensure that the combination ‘makes sense’ and does not contradict the traditional use of the individual ingredient/s e.g.,. combining highly dilute homoeopathic preparations with highly concentrated herbal extracts is not consistent with the homoeopathic paradigm and may alter the efficacy of the ingredients in the formulation.

|  |  |
| --- | --- |
| Information | **Example:**  **Traditional indication for a multi traditional paradigm medicine**  A listed medicine includes individual herbal ingredients that are drawn from traditional uses in Traditional Chinese Medicine and Ayurveda. There is no history of use of the particular herbal combination, but there is sufficient evidence of use of the individual herbs for the indication in both Chinese medicine and Ayurveda paradigms.   * Non-allowable indication (refers to whole listed medicine): “Used traditionally in Chinese medicine and Ayurvedic medicine to promote muscle relaxation’. * Allowable indication (refers to ingredients): ‘These herbs are used traditionally in Chinese medicine and Ayurvedic medicine to promote muscle relaxation’. |

### Scientific indications

Scientific indications are those that refer to modern conventional medicine paradigms and that are supported by quantitative scientific data derived from human clinical trials, observational studies in humans and/or systematic reviews.

When choosing a scientific indication, the sponsor should:

* ensure the body of evidence is based on scientific data obtained in humans from a clinical setting
* ensure the indication has the same meaning and intent as the therapeutic benefit specified in the evidence sources

Scientific indications cannot:

* refer to traditional paradigms or be based on evidence of traditional or historical use
* imply a higher level of certainty in the indication than warranted by the body of evidence

### Cross-paradigm indications

A listed medicine can have a combination of traditional and scientific indications where:

* the efficacy of an ingredient in the medicine is supported by both evidence of traditional use and scientific evidence (cross-evidence base ingredient)
* the medicine contains both traditional and non-traditional ingredients with associated traditional and scientific indications (cross-evidence base medicine)

In this case, the traditional and scientific indications should be assessed separately, not as one single mixed-category indication. It is important that the indications for the listed medicine accurately reflect the evidence base for the indication(s). The evidence package should separately demonstrate the efficacy of your medicine for each traditional and scientific indication.

|  |  |
| --- | --- |
| Information | **Cross-paradigm indications**  **Example 1:**  If efficacy can be demonstrated, a medicine that contains *Echinacea purpurea* and ascorbic acid (vitamin C) can have the following indications listed in the ARTG:   * ‘Traditionally used in Western herbal medicine to enhance/improve/promote immune system function’ * ‘Maintain/support immune system health’   **These indications can be combined on the medicine’s label as follows:**  ‘This medicine has been formulated from traditional and modern ingredients for a healthy immune system function. *Echinacea purpurea* has been traditionally used in Western herbal medicine to promote immune system function. Vitamin C supports immune system health’.  **Example 2:**  If efficacy can be demonstrated, a medicine that contains evening primrose seed oil (EPO) with a high gamma-linolenic acid content can have the following indications listed in the ARTG:   * ‘Traditionally used in Western herbal medicine to relieve symptoms of mild eczema/dermatitis’ linked symptom indication: ‘soothe/relieve skin inflammation’ * ‘Anti-inflammatory/relieve inflammation’   These indications can be combined on the medicine’s label as follows:  ‘Evening primrose seed oil (EPO) has been used traditionally in western herbal medicine to relieve symptoms of mild eczema, such as skin inflammation. Gamma-linolenic acid is a component of EPO that has anti-inflammatory properties.’ |

## Level of indications

Listed medicines may only use low level indications selected from the [Permissible Indications Determination](https://www.tga.gov.au/therapeutic-goods-determinations). Indications permitted for use in listed medicines may only refer to:

* health enhancement
* health maintenance
* prevention or alleviation of a non-serious vitamin or mineral dietary deficiency; or
* a non-serious form of a disease, ailment, defect or injury.

For the purposes of determining the level of evidence that is expected to support the efficacy of listed medicines, we classify scientificindications into two levels, specific and non-specific. Traditional indications are not classified into ‘specific’ and ‘non-specific’ as the evidence expectations for non-specific and specific traditional indications are fundamentally the same. In addition, the terminology used in traditional medicine paradigms does not easily fit in this classification system.

Classifying scientific indications as specific or non-specific is a means to determine when it is acceptable for sponsors to hold a lower level of evidence. This is in recognition that, while all permitted indications are low level (to maintain a low risk medicine), some go beyond general health maintenance claims and refer to enhancement of health or include an effect on a specific target. Accordingly, the efficacy of listed medicines with these types of indications should be supported by a higher level of evidence.

Guidance on the minimum evidence requirements for specific or non-specific indications is included in 4[.4 What types of evidence are expected for each type of indication?](#_What_types_of)

|  |  |
| --- | --- |
| Information | **Note:**  For the purposes of these guidelines, when considering non-specific or specific indications, the following definitions apply:   * **Symptoms:** Any subjective evidence of disease or of a patient's condition, that is, such evidence as only able to be perceived by the patient, for example: muscle pain. * **Sign**: The objective evidence of disease or of a patient’s condition, that is, such evidence that is apparent to a third party, for example: skin rash. * **Condition:** Any deviation(s) from the normal structure or function of the body, as manifested by a characteristic set of signs and symptoms. * For a condition to be ‘**named**’, it is mentioned/specified/identified in the indication. |

### Non-specific indications

Non-specific indications for listed medicines refer to general health and wellbeing, such as:

* health maintenance
* relief of general symptoms
* general vitamin, mineral or nutritional supplementation (only where there are no other references to a specific health benefit)

[Table 3](#ColumnTitle_4) in conjunction with [Figure 4](#Figure_4) explains (with examples) the types of indications that are considered to be non-specific.

### Specific indications

A scientific indication for listed medicines that goes beyond maintaining general health and wellbeing is classified as specific. Specific indications refer to:

* health enhancement, with therapeutic actions such as: enhance, reduce, improve, increase, promote, relieve, decrease or those with similar intent
* reduction of occurrence or frequency of a condition or symptoms, a discrete event or a named condition
* management or relief of symptoms linked to a named condition/disease/disorder
* nutritional supplementation that restore, correct or modify a physiological or mental process/function/state

Indications referring to symptoms can be non-specific or specific depending on the particular target or action. **Table 3** in conjunction with **Figure 5** explains (with examples) the types of indications that are considered to be specific or non-specific.

Table : Summary of specific and non-specific indications

Instructions for using table:

1. The table should be considered in its entirety to best determine which category an indication falls in.
2. Start from the top of the table, and work sequentially through the numbered subcategories, paying close attention to the exclusions.
3. It is highly recommended to double check the classification of indications by using the decision tool at [Figure 5](#Figure_4).

|  |  |  |  |
| --- | --- | --- | --- |
|  | Category | Health Benefit | Example of an indication on label |
| **SPECIFIC** | **1** | **Health enhancement**  Represented to restore, correct or modify (increase or decrease) a physiological or mental process/function/state.  *Excludes indications that refer to symptoms or signs not related to a named condition (i.e. indications that fit category 6).* | ‘Helps enhance blood circulation to the peripheral areas of the body (legs, hands and feet)’  ‘Enhance healthy digestion’ |
| **2** | **Reduce risk or occurrence or frequency of symptoms, a discrete event or a named condition**  This includes reducing the duration or severity of symptoms, a discrete event or a named condition. | ‘Help reduce occurrence of symptoms of medically diagnosed Irritable Bowel Syndrome’  ‘Helps reduce occurrence of abdominal bloating’  ‘Relieve urinary frequency’  ‘Helps reduce the occurrence of nose bleeds’ |
| **3** | **Management or relief of symptoms/ signs linked to a named condition**  Improved quality of life without resolution of the named condition.  *Excludes indications that refer to symptoms or signs not related to a named condition (i.e. indications that fit category 6)* | ‘Relieve symptoms of hayfever’  ‘Improve bowel regularity’  ‘Decrease symptoms of mild arthritis’ |
| **4** | **Specific supplementation indications**  Indications about supplementation that are represented to restore, correct or modify (increase or decrease) a physiological or mental process/function/state. | ‘Helps enhance/promote/increase absorption of dietary (state vitamin/mineral/nutrient)’  ‘Helps prevent dietary (state vitamin/mineral/nutrient) deficiency’ |
| **NON-SPECIFIC** | **5** | **Health maintenance**  Normal physiological effects of substances in growth, development and normal functions of the body.  *Excludes indications that refer to or imply enhancement of physiological functions, growth and development beyond the existing levels.* | ‘Maintain general health and wellbeing’  ‘Support healthy digestion’  Exclusion example: ‘Maintain/support joint health in elderly people’ |
| **6** | **Relief of general symptoms/signs**  Symptoms or signs not related to a named condition. | ’Relieve skin redness’  ‘Relieve muscle pain’ |
| **7** | **General supplementation indications**  *Indications about supplementation that exclude indications that fit category 4* | ‘Maintain calcium levels in the body’  ‘Maintain magnesium within normal range’ |

|  |  |
| --- | --- |
| Information | **Note:**  **Maintain/support claims**  The presence of the term ‘maintains/supports’ in a permitted indication does not automatically mean that the indication relates to a ‘health maintenance’ action and therefore, is a non-specific indication. When determining whether your indication is about health maintenance or health enhancement, you should consider the indication holistically, considering factors such as the target population or the nature of the condition that is referred to in the indication e.g.,.   * ‘Maintains/supports healthy bone density’ when in the context of postmenopausal women would be considered ‘health enhancement’, as bone density decreases as a normal process of ageing in this subpopulation. Therefore, referring to maintaining bone density in this subpopulation goes beyond normal functions of the body. |

|  |  |
| --- | --- |
| Information | **Note Linking ‘parent’ permitted indications with ‘symptom’ permitted indications in ARTG entries.**  When entering a medicine in ELF, indications referring to general symptoms can be linked with an indication referring to 'the symptoms of’ a disease or condition (‘parent indication’). Parent indications are generally considered ‘specific indications’ as they refer to a named disease or condition.  When linking general symptom indications with an indication referring to symptoms of a disease or condition, you are expected to hold evidence for the selected symptoms as it relates to the disease or condition in the parent ‘specific’ indication. This may come from a variety of evidence sources.  If you do not hold that evidence, then you should not link that symptom indication to the parent indication (that is, the indication can be included separately in the ARTG entry and efficacy demonstrated by using separate evidence). You should ensure that the indication on the medicine label is truthful and an accurate representation of the body of evidence.  **Selecting indication qualifiers for permitted indications in ARTG entries**  When you enter your medicine in ELF, you may choose to select indication qualifiers (such as population qualifiers e.g.,. ‘in women’ or ‘time of use’ qualifiers e.g.,. ‘after eating’) to make a permitted indication more targeted and better align with the efficacy evidence you hold for your medicine. Although adding a qualifier does not necessarily make a non-specific indication become specific, please take care to ensure that the selection of a qualifier is relevant to the evidence you hold. |

[Figure 5](#Figure_4) is a guidance tool designed to assist you with the process of classifying indications as specific or non-specific. While the tool is intended to increase the consistency of classification, we acknowledge that there may be some indications that are difficult to categorise for individual medicines. When considering your indication using the decision tool, some factors that should be considered include:


* the target population
* indication qualifiers
* the nature of the condition referred to in the indication
* whether combining indications on the medicine label changes the specificity of the indications

Further, it is strongly recommended that when determining whether your indication is specific or non-specific, you check to see whether there are similar or related indications in the Permissible Indications Determination. For example, the Determination includes both ‘maintains/supports skin healing/repair/regeneration’ and ‘enhance/improve/promote skin repair/healing’. In this instance, the former indication is more likely to be considered as non-specific, when the target population is generally healthy adults.

We reiterate that when the TGA conducts a compliance review of a listed medicine, the medicine is considered on its individual merits. If you consider there is ambiguity in classifying your medicine’s indication, you may wish to include a justification or rationale in your evidence package for classifying an indication as non-specific or specific to show the TGA how you came to your conclusion.

Figure : Decision tool for determining specific/non-specific indications

**Note**: In the PDF version of this document (available on the consultation website) the examples in this Figure are provided as embedded ‘hover’ text for screen viewing.



#### Explained examples: bolded indications in the decision tool

The indications below (used as examples in the decision tool provided in **Figure 5**) have been further explained to help you understand the thought processes involved when using the tool.

**‘Maintain healthy digestion’**

1. Is the indication represented to restore, correct or modify (increase or decrease) a physiological or mental process/function/state?

No – this indication is represented to maintain healthy digestion in a healthy person, and therefore, does not represent to modify any physiological function.

Conclusion: Non-specific

**'Relieve skin redness’**

1. Is the indication represented to restore, correct or modify (increase or decrease) a physiological or mental process/function/state?

Yes – to relieve skin redness, physiological processes (such as chemical messengers affecting blood vessel dilation) must be modified in a patient to decrease the level of redness in the skin.

1. Does the indication explicitly refer to 'symptoms of'?

No – the indication does not mention the words ‘symptoms of’.

1. Does the indication suggest an action of relief?

Yes – the indication refers to the relief of skin redness.

(Note: changing the indication to ‘**reduce** skin redness’ or ‘**decrease** skin redness’—as allowed in the Permissible Indications Determination—will also answer ‘Yes’ to this question. Reducing or decreasing skin redness has the same meaning and intent as relieving skin redness. However, the words ‘Decrease/reduce’ in indications such as ‘Decrease/reduce time to fall asleep’ does not have the same meaning and intent as relief.)

1. Does the indication refer only to a single symptom/sign?

Yes – skin redness can be either subjective or objective as this can be perceived or observed by the patient (i.e., the patient can see or feel the skin redness) or to a third party (i.e. a third party can see the skin redness). An average person would be able to conclude that the skin is indeed red and cannot deduce the disease/condition that is causing this sign/symptom.

Conclusion: Non-specific

**'Temporarily relieve mild fluid retention'**

1. Is the indication represented to restore, correct or modify (increase or decrease) a physiological or mental process/function/state?

Yes – relieving mild fluid retention is restoring or correcting the amount of fluid that has been trapped in the tissues of the body.

1. Does the indication explicitly refer to 'symptoms of'?

No – the indication does not mention the words ‘symptoms of’.

1. Does the indication suggest an action of relief?

Yes – the indication refers to the relief of mild fluid retention.

1. Does the indication refer only to a single symptom/sign?

No – fluid retention is not a subjective or an objective evidence of a disease/condition. Fluid retention is manifested by a characteristic set of signs and symptoms such as swelling of the extremities and pitting of the skin thus making it a condition that is named in the indication.

Conclusion: Specific

**‘Helps maintain weight after weight loss’**

1. Is the indication represented to restore, correct or modify (increase or decrease) a physiological or mental process/function/state?

Yes – the indication is represented to help maintain weight after weight loss by continuously correcting or modifying the physiological process/function, such as increasing one’s metabolism, reducing the absorption of fat or suppressing the appetite.

1. Does the indication explicitly refer to 'symptoms of'?

No – the indication does not mention the words ‘symptoms of’.

1. Does the indication suggest an action of relief?

No – the indication does not refer to the relief of anything.

Conclusion: Specific

**‘Helps maintain healthy blood sugar’**

1. Is the indication represented to restore, correct or modify (increase or decrease) a physiological or mental process/function/state?

No – this indication is represented to maintain existing healthy levels of blood sugar in a generally healthy person, and therefore, is not restoring, correcting or modifying any physiological functions.

(Note: Indications referring to the management, balance and/or control of biomarker levels, ratios and ranges are not permissible indications and cannot be advertised.)

Conclusion: Non-specific

**‘Maintain/support testosterone level in older males’**

1. Is the indication represented to restore, correct or modify (increase or decrease) a physiological or mental process/function/state?

Yes – the indication is represented to correct the level of testosterone in older males by helping them maintain those levels—whose levels would otherwise naturally decline with older age.

(Note: Without the ‘in older males’ qualifier, the indication would represent to maintain levels in a healthy adult; therefore, would answer ‘No’ to this question.)

1. Does the indication explicitly refer to 'symptoms of'?

No – the indication does not mention the words ‘symptoms of’.

1. Does the indication suggest an action of relief?

No – the indication does not refer to the relief of anything.

Conclusion: Specific

**‘Aid/assist digestion of lactose’**

1. Is the indication represented to restore, correct or modify (increase or decrease) a physiological or mental process/function/state?

Yes – the indication is represented to help the digestion of lactose by either directly providing/increasing more lactase enzyme or modifying the physiological function of digesting lactose by other means (e.g.,. modifying the gut microbiota).

(Note: Depending on the mechanism of action of the indication, the words ‘aid/assist’—which is synonymous with ‘support/helps’—can either mean to increase/decrease something or to maintain it. Where ambiguity is present, sponsors should justify why they have categorised it one way or another, and how that is suitable based on their medicine’s design. For example, a sponsor may justify that their ‘aid/assist nail growth’ indication is designed and presented for healthy individuals and is categorised as ‘non-specific’ because it is maintaining existing healthy levels of nail growth.)

1. Does the indication explicitly refer to 'symptoms of'?

No – the indication does not mention the words ‘symptoms of’.

1. Does the indication suggest an action of relief?

No – the indication itself does not refer to the relief of anything—only refers to the digestion of lactose. Although *as a result* of enhanced lactose digestion, it may relieve symptoms such as bloating and flatulence, it does not make sense to ‘relieve’ digestion of lactose.

Conclusion: Specific

## What types of evidence are expected for each type of indication?

The different types of indications and the corresponding types of evidence that may be included in evidence packages are outlined in **Table 4**. These are general minimum evidence requirements to be included in an efficacy evidence package, which may not necessarily be sufficient in all cases. Additionally, the evidence sources should contain independent sources of information e.g.,. two publications referencing the same clinical trial or information are not considered to be two independent sources of information.

Regardless of what evidence is used, all evidence sources should meet the quality and relevance requirements as set out in these guidelines. Just the fact that a study is published should not be relied on to indicate that the study is of sufficient quality. Often clinical studies conclude that an effect *might* be present, but that further investigation is needed. If there are specific areas of concern for an evidence source, a justification should be included in your evidence package for why these areas of concern have no impact on the validity of your conclusions of your medicine’s efficacy. Sponsors are encouraged to provide additional evidence to strengthen an evidence package, particularly if any of the pivotal studies are limited in some way.

The options presented in **Table 4** may not be suitable for every medicine. These requirements represent the lowest threshold below which the efficacy of the medicine cannot be reasonably assessed. This means that a minimum number of evidence sources from the categories of evidence described above should be included in your evidence package to be critically appraised as part of the body of evidence. Please see [5.1 How to critically appraise the body of evidence](#_Critical_appraisal_of).

As with all other aspects of an evidence package, where a sponsor diverges from these guidelines, a justification should be included in the evidence package to demonstrate to the TGA that your medicine is efficacious despite this divergence.

Table : Minimum evidence requirements for scientific and traditional indications

|  |  |  |  |
| --- | --- | --- | --- |
| Minimum evidence requirements | | | |
| **Scientific indications** | | | |
| **Minimum evidence requirements** | **Non-specific indications:** | | **Specific indications:** |
| Minimum of two from Category B or Category C | | Minimum of one from Category A  **OR** Minimum of one from Category B AND two from Category C |
| **Category A** | **Category B** | | **Category C** |
| Double blind randomised controlled trials (including cross-over trials) | Observational studies, for example: cohort and case-controlled studies | | Non-systematic, generalised reviews – including databases |
| Systematic reviews | Comparative studies (non-controlled) | | Publicised international regulatory authority articles |
| Evidence-based reference texts - ***scientific*** |
| Scientific monographs |
| **Traditional indications** | | | |
| **Minimum evidence requirements** | | Minimum of two from ‘Traditional Evidence to support tradition of use’ | |
| **Traditional Evidence to support tradition of use** | | | |
| * Materia medica * Official pharmacopoeias * Monographs * Publications from various international regulatory authorities * Texts that are relevant to the traditional paradigm * Well-recognised evidence-based reference texts | | | |

### Using ‘clinically proven’ in your indications

Use of the claim ‘clinically proven’ in a scientific indication implies a higher level of certainty in the effectiveness of the medicine: that is, the medicine has been clinically trialled and proven to be efficacious. Such a claim should be supported unequivocally by robustly designed, published peer-reviewed clinical trial/s conducted on the actual medicine (i.e. not based on trials of individual ingredients found in the medicine) being advertised, or an identical formulation and dose (as a minimum).

Similarly, using terms such as ‘clinical’, ‘clinically’, ‘scientifically’ coupled with ‘trialled’, ‘researched’ or ‘tested’ implies a higher level of certainty of the medicine’s effectiveness. Unless these claims are supported by well-designed clinical studies on the actual medicine in question, these terms should not be used as they may mislead consumers about the effectiveness of the medicine.

Due to the additional evidence required to support the use of these terms, indications that include these types of claims are classified as specific scientific indications. Listed medicines with traditional indications should not use these terms, as this is misleading to consumers.

### Vitamin/ mineral/ nutrient supplementation

#### Supplementation claims

For the purposes of these guidelines, a supplementation claim for a listed medicine is an explicit or implicit statement that a medicine provides a vitamin/mineral/nutrient for oral ingestion, which is ordinarily consumed from the diet (i.e. from food). A supplementation claim simply conveys that by consuming the medicine, the consumer will ingest additional vitamin/mineral/nutrient than otherwise ingested from dietary sources alone.

Examples of supplementation claims in relation to the mineral magnesium are:

* ‘magnesium supplement’
* ‘dietary magnesium supplement’
* ‘source of magnesium’

A supplementation claim is not considered a therapeutic indication and, in general, such claims are not included in the [Permissible Indications Determination](https://www.tga.gov.au/therapeutic-goods-determinations).

While a supplementation claim can be included on a medicine label (providing the statement is truthful), the medicine must also have at least one indication from the Permissible Indications Determination (a Permitted Indication) in the medicine’s ARTG entry and on the medicine’s label.

**Evidence required to support supplementation claims**

A listed medicine can make a named vitamin/mineral/nutrient ‘supplementation claim’ on the medicine label, if the medicine:

* provides at least 25% of the Recommended Dietary Intake (RDI), Adequate Intake (AI) or Nutrient Reference Value (NRV); and
* the nutrient is in a form able to be absorbed by the body

|  |
| --- |
| **Recommended Dietary Intake (RDI)** – the average daily intake level that is sufficient to meet the nutrient requirements of nearly all (97-98%) healthy individuals in a particular life stage and gender group.  **Adequate Intake (AI)** – the recommended average daily intake level based on observed or experimentally determined approximations or estimates of nutrient intake by a group (or groups) of apparently healthy people that are assumed to be adequate.  **Nutrient Reference Value (NRV)** – the daily amount of nutrients required for good health, as well as an upper safe level of nutrient intake. |

#### Indications with special evidence requirements

All scientific indications that refer to the effect of a stated vitamin/mineral/nutrient are categorised as specific or non-specific using the exact same principles as any other scientific indication (refer to **Table 3**  and **Figure 5** on the categorisation of scientific indications).

However, as specific exceptions, the TGA will accept the following two indications to be supported by the same evidence requirements as supplementation claims:

1. ‘Maintain/support (state vitamin/mineral/nutrient) levels in the body’
2. ‘Maintain/support (state vitamin/mineral) within normal range’

A requirement included in the [Permissible Indications Determination](https://www.tga.gov.au/therapeutic-goods-determinations) associated with the use of the above two indications is that the medicine label must include one of the following label statements:

*(Vitamins/minerals/nutrients/dietary supplements) can only be of assistance if dietary intake is inadequate OR*

*(Vitamins/minerals/nutrients/dietary supplements) should not replace a balanced diet (or words to that effect)*

The rationale for the TGA accepting special evidence requirements for the above two indications is that these indications (with their required label statements) only imply that additional oral ingestion (to that ingested from dietary sources) of the stated vitamin/mineral/nutrient will help the consumer reach the recommended consumption of the nutrient. That is, a consumer would have similar expectations for these indications as they would for similar supplementation claims. Accordingly, these indications can be supported by providing at least 25% of RDI, AI or NRV. The requirements of supplementation claims and the above two indications have been summarised in **Table 5** below.

Table : Minimum evidence requirements of supplementation claims and two permissible indications

|  |  |
| --- | --- |
| Claims/indications | Minimum evidence requirements |
| **Supplementation claims** | 1. Provides at least 25% of RDI, AI or NRV 2. Nutrient is in a form that can be absorbed by the body 3. Medicine must also have at least one permissible indication in the medicine’s ARTG entry and on the medicine label. |
| **Permissible indications with special evidence requirements**   1. ‘Maintain/support (state vitamin/mineral/nutrient) levels in the body’ 2. ‘Maintain/support (state vitamin/mineral) within normal range’ | 1. Provides at least 25% of RDI, AI or NRV 2. Nutrient is in a form that can be absorbed by the body |

### Biomarker indications

Biomarkers are molecules in the body that can be measured to monitor a physiological process or monitor a condition or disease. Blood glucose is an example of a biomarker for diabetes, where high levels may indicate the onset or progress of the disease.

The [Therapeutic Goods (Permissible Indications) Determination](https://www.tga.gov.au/therapeutic-goods-determinations) only includes low level biomarker indications relating to general health:

* ‘Aid/assist/helps glucose/sugar/carbohydrate metabolism’
* ‘Helps maintain/support healthy cholesterol’

In addition, indications for listed medicines should only target healthy individuals with biomarker levels that lie within the normal healthy range. Sponsors are encouraged to consider their biomarker indications using the [decision tool](#Figure_4) provided in Figure 5 to determine the appropriate level of evidence required to support their medicine’s efficacy. An example of a biomarker indication is included in the tool to provide clarification.

Sources of evidence used to support the efficacy of listed medicines with biomarker permitted indications should show a therapeutic effect in the population that is representative of, or can reasonably be extrapolated to, the general healthy Australian demographic.

If an evidence source uses study populations with baseline biomarker levels outside normal healthy levels, the data should not be automatically extrapolated to a medicine with a biomarker permitted indication without further justification (for why it can be extrapolated) in the evidence package. Evidence sources using diseased populations may not be relevant as the pathophysiology of the disease may alter the way a substance works in the body.

Because of the continuum between health and disease, all biomarker and risk reduction indications for listed medicines should include a disclaimer that recommends consumers to consult a healthcare practitioner if they are concerned about their health status.

|  |  |
| --- | --- |
| Information | The assessed listed [AUSTL (A)] pathway may provide an option for listed medicines to make biomarker indications beyond those included in the permitted indications list when the efficacy of the medicine has been assessed by the TGA. Refer to [Assessed listed medicines evidence guidelines](https://www.tga.gov.au/publication/assessed-listed-medicines-evidence-guidelines) for more information. |

### Weight loss indications

It has been suggested that a mean reduction in Body Mass Index (BMI) of approximately 1 kg/m2 (that is, one BMI unit) across a population could have a significant impact on the prevalence of obesity and overweight individuals within the population13. There are clinical studies[[5]](#footnote-5),[[6]](#footnote-6) that support the notion that a 5%–10% weight loss impacts positively in reducing the risk of type 2 diabetes, cardiovascular disease, hypertension, and psychological functioning (such as mood, body image and binge eating).

Indications relating to weight loss or weight management require scientific evidence that demonstrates the weight loss is clinically significant, unlikely to be attributed to diet and exercise alone and can be maintained after the initial weight loss period.

***Amount of observed weight loss between obese and overweight individuals***

In Australia, registered medicines targeting obese individuals [those with a Body Mass Index (BMI) over 30 kg/m2] are required to demonstrate an absolute reduction of the initial body weight of at least 10% over a one year period[[7]](#footnote-7). However, this amount of weight loss may not be appropriate for individuals who are moderately overweight (those with a BMI between 25 to 30 kg/m2), but otherwise healthy.

Obese individuals expend more energy for a given activity because of their larger body mass. Therefore, in a weight loss context, for the same level of dietary intake and physical activity, the amount of weight lost will be different for obese (BMI >30 kg/m2) and overweight individuals (BMI 25-30 kg/m2). This difference is likely to become increasingly significant as the mean BMI of study participants increases.

As such, studies that include obese participants with a BMI >30 kg/m2 cannot be automatically generalised to overweight, but otherwise healthy, individuals (BMI 25 – 30 kg/m2). If a sponsor chooses to include such studies in their evidence of efficacy package, a justification (substantiated by evidence) for the scientific rationale behind such a generalisation should be included.

***Evidence of clinically significant weight loss***

In weight loss clinical trials, the control group commonly achieves some degree of weight loss due to changes in lifestyle, such as dietary intake and exercise. It is possible for lifestyle modifications alone to give small weight loss results[[8]](#footnote-8),[[9]](#footnote-9),[[10]](#footnote-10),[[11]](#footnote-11). Evidence supporting the efficacy of listed medicines with weight loss indications should demonstrate that the degree of weight loss is clinically significant and is the result of the actions of the medicine (that is, unlikely to be attributed to diet and exercise alone).

|  |  |
| --- | --- |
| Information | **What is clinically significant weight loss?**  In relation to weight loss indications, clinical significance means a significant weight reduction that is maintained over time (please see caveat below for temporary weight loss indications). |

For listed medicines, given that they can only make low level indications, the TGA accepts a minimum level of weight loss of 5% reduction of the initial body weight over six months, as it likely represents a clinically significant level of weight loss. Weight loss of less than 5% of the initial body weight is unlikely to be clinically significant and therefore inadequate to support the efficacy of listed medicines with weight loss indications.

Therefore, in weight loss studies in which the participants are overweight but otherwise healthy, we expect the study to demonstrate:

* an overall weight loss of at least 5% of the initial body weight in the treatment group
  + the overall weight loss should be at least 3 % greater in the treatment group than in the placebo/control group in randomised clinical trials; and
  + at least 5 % difference in the treatment group than in the placebo/control group in non-randomised clinical trials, as this demonstrates that the weight loss is likely due to the treatment and not the consequence of lifestyle changes or placebo effects
* that the overall weight loss **and** the difference between groups is statistically significant
* at least 50% of the participants in the treatment group should achieve at least a 5% reduction of the initial body weight, making it ‘more likely than not’ that consumers will achieve a clinically significant benefit from the appropriate use of the medicine. This demonstrates that the effect of an ingredient or medicine is consistent across the whole target population

***Study duration for weight loss***

A number of international and local guidance documents have adopted a minimum study duration of at least 12 months for weight loss studies, including:

* The European Medicines Agency ‘Guideline on clinical evaluation of medicinal products used in weight management’[[12]](#footnote-12). which provides guidelines for clinical studies examining the efficacy of weight loss medications.
* The Food and Drug Administration draft guidance document titled ‘Guidance for industry developing products for weight management’[[13]](#footnote-13), which outlines the conditions under which a product can be considered effective for weight management.
* The 2013 AHA/ACC/TOS Guideline for the management of overweight and obesity in adults[[14]](#footnote-14), which recommends long term comprehensive weight loss programs.
* The National Health and Medical Research Council (NHMRC) ‘Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia’[[15]](#footnote-15) which includes statements regarding the duration of weight loss interventions.

Initial weight loss is commonly followed by a gradual weight regain. This phenomenon has been observed in studies where the treatment intervention occurred for the entirety of the study, as well as in studies where the treatment intervention occurred for a specified length of time and the participants were monitored for the remainder of the study period. There have been several studies in which overweight/obesity interventions (including diet/exercise alone) were observed to cause weight loss in a relatively short time frame, frequently reaching a peak within 6 months of the start of treatment, after which study participants gradually began to regain weight[[16]](#footnote-16),[[17]](#footnote-17).

For the purposes of listed medicines, a reasonable timeframe to achieve a significant degree of weight loss (at least 5% reduction of initial body weight) and to demonstrate clinical significance is considered to be six months. Short study periods fail to demonstrate the purported benefit of a treatment in full, including the ability to sustain weight loss for longer periods of time. Therefore, study lengths will generally need to be at least six months in duration to support the efficacy of listed medicines with weight loss indications. For information about study duration for temporary weight loss indications, see below.

However, it may be possible to demonstrate clinically significant weight loss through a rigorously designed study of less than six months duration when there is sufficient follow up after the treatment intervention. Adequate follow up is critical because weight regain is a common occurrence following a weight loss intervention, and in the absence of follow up data demonstrating otherwise, it is reasonable to expect that weight regain will occur.

We therefore expect that if the treatment intervention period in a given study is less than six months, there should be follow up data demonstrating at least 5% reduction of the initial body weight at the six-month point (if not later).

***Study duration for temporary weight loss indications***

For indications specifically referring to *temporary* weight loss, which must carry the mandatory label statement advising consumers that the ‘Weight loss may not be maintained for longer than 3 months’ (which clarifies for consumers that the weight loss they achieve may only be for a short term), may be appropriate to rely on clinical studies that show at least a 5% reduction of the initial body weight over a minimum duration of three months.

***Use of terminology that implies weight loss***

Terminology that implies the potential for weight loss (e.g.,. through increased fat metabolism) cannot be used to suggest weight loss unless the sponsor holds appropriate evidence. **Table 6** provides examples of terms that imply weight loss. If a sponsor uses such terms in indications or claims to imply weight loss, they will need to hold evidence that demonstrates clinically significant weight loss as described above.

Table : Terms that should not be substituted for the term ‘weight loss’ in an indication

|  |  |  |  |
| --- | --- | --- | --- |
| **Metabolism** | **Body shape and composition** | **Weight related** | **Appetite** |
| Increased metabolic rate  Enhanced metabolism Enhanced fat metabolism Thermogenesis Increased calorie burning | Fat loss Increased muscle mass Cellulite Slimming | Weight maintenance Weight control Weight management | Appetite suppression Enhanced satiety  Fasting |

Table 7 summarises the characteristics scientific evidence should have to support the efficacy of listed medicines with weight loss indications.

Table : Summary of scientific evidence to support weight loss

|  |  |
| --- | --- |
| Scientific evidence to support weight loss |  |
| For listed medicines with indications relating to weight loss in overweight individuals (BMI 25-30 kg/m2), supporting scientific evidence should demonstrate:   * A mean overall loss of at least 5% initial body weight in the treatment group: * the difference between the treatment and placebo group must be statistically significant (p<0.05) * the difference between the treatment group and the control group should be a mean overall loss of 5% for non-randomised clinical trials and 3% for randomised clinical trials * the treatment group should show 5% greater weight loss than placebo group for example: if placebo group showed 2% weight loss, the treatment group should show at least a mean weight loss of 7% of initial body weight; and * at least 50% of participants in the treatment group must have achieved a loss of at least 5% of initial body weight; and * the above must be demonstrated at the 6-month point from the onset of the intervention period; or * for ‘temporary’ weight loss indications, the study duration should be at least 3 months. | |

# How to document and present evidence

When the collected evidence has been assessed for quality and relevance to the medicine, an evidence package should be collated to provide to the TGA if requested to do so [under subsection 31(2) of the Act].

|  |  |
| --- | --- |
| Information | Evidence packages provided to the TGA as part of an evidence review are not required to comply with a specified format. However, following the guidance set out in this section will increase your ability to show the TGA that your medicine is efficacious and meets the requirements as set out in [[1.2 Sponsors’ legal responsibilities](#_Why_sponsors_have)](#_Why_sponsors_have).  Evidence packages can be submitted using the existing [Evidence package checklists](https://www.tga.gov.au/form/listed-medicines-evidence-package-checklists) (currently under review) available on the TGA website. Sponsors may also choose to follow a similar format as demonstrated in the example evidence package for vitamin B12 in [Appendix 3](#_Appendix_3:_Example). |

The purpose of an evidence package is to provide evidence to the TGA to demonstrate that your medicine will do what it says it will do (i.e. it will produce the therapeutic effect(s) described by its indications). Therefore, an evidence package should:

* Show that the data or information collected is a true and accurate representation of the evidence landscape by:
  + conducting an objective, comprehensive and transparent review of the literature relating to the indications for the medicine
  + selecting to include literature that is of high quality and relevant to the medicine
  + demonstrating that assumptions made are valid, biases do not impact the data validity and evaluating the impacts of competing data on the conclusions
* Provide reasons for why, based on the body of evidence collected, the medicine is likely to produce the therapeutic effects described by the indications.

An evidence package should include:

* Medicine identification details:
  + ARTG identification number
  + Medicine name
  + Sponsor name
  + Sponsor contact details
* General medicine details:
  + Dosage form
  + Route of administration
  + Intended population (e.g.,. age, gender, ethnicity, health conditions)
  + Recommended dose
  + Maximum recommended daily dose (MRDD)
  + Directions for use
  + Duration of use (where relevant)
  + Cautions and contraindications
* Active ingredient/s
* Method of preparation for active ingredient/s
* Indication/s
* Details of the search strategy used
* A critical appraisal of the body of evidence generated from the literature searches, including [justification](#_Justifications)s for any data gaps or discrepancies
* A comprehensive list of references

## Critical appraisal of the body of evidence

### Critical appraisal

An evidence package should include a critical appraisal of the body of evidence. The purpose of a critical appraisal is to demonstrate that the sponsor’s conclusion that the medicine will likely result in the therapeutic effect described by the indication is logical, reasonable and based on data that we have confidence in to be true and accurate.

If a sponsor chooses to include sources of evidence that are weak or of low quality, the critical appraisal should acknowledge these weaknesses and provide an assessment of how and why these weaknesses do not impact on your conclusion that their medicine is efficacious. In this situation, holding a combination of moderate and low-quality sources, or several weak or low-quality sources that meet the relevance and quality criteria *when combined*, may help strengthen arguments to support your conclusion. A critical appraisal should:

* be focused on evidence sources that are most relevant to the research question and are of high quality
* avoid relying on irrelevant or weak evidence sources
* distinguish evidence from opinion, assumptions, misreporting and belief
* assess the validity of the results and conclusions in the relevant literature
* assess the impact of competing datasets
* assess the impact of any potential for bias
* assess the clinical significance of the findings in the literature

If you are unable to provide a strong case to conclude that the medicine will likely result in the therapeutic effect described by the indication, then we recommend that you reconsider the design of your medicine (for example: indication, formulation, dose, dosage form or target population).

### Balanced view of the evidence landscape

Before a medicine is listed in the ARTG, a sponsor should carefully consider the available body of evidence and be satisfied that the **overall** balance of evidence supports the efficacy of your medicine (that is, by considering both evidence for and against the therapeutic effect of interest). A well-constructed literature search will help to identify the overall evidence landscape related to a particular indication.

The evidence you collate into your evidence package should consist of sources that are largely consistent with the general evidence landscape. In other words, a reasonable person making an objective assessment of all relevant evidence about the medicine would conclude that there is good evidence to support your medicine’s efficacy rather than against it. The medicine’s indications should not, indirectly or by implication, lead consumers to believe that the medicine will assist in a health benefit that is not supported by the balance of evidence.

For scientific indications, a sponsor should regularly check for new relevant data to ensure that the balance of evidence continues to support the efficacy of their medicine, for the time the medicine is listed on the ARTG. This is best achieved by building and maintaining an up-to-date body of evidence for the medicine. Over time, the evidence landscape supporting a particular therapeutic use may change as research and technology advance. Newer clinical studies may augment the strength of evidence related to an indication or they may be inconsistent with previous findings. Maintaining a comprehensive and up-to-date body of evidence for your medicine will help ensure that your indications remain valid, not misleading and consistent with the scientific evidence for the life of your medicine.

### Justifications in your critical appraisal

Typically, the evidence that is relied on to demonstrate the efficacy of listed medicines is not derived from clinical studies conducted on the medicine itself. Instead, the majority of the evidence comes from the available literature. Consequently, there can often be information gaps or discrepancies between sources of evidence. Where a sponsor elects to include evidence sources that have gaps or discrepancies in their evidence package, justifications should be included as part of the sponsor’s critical appraisal of the evidence. The purpose of these justifications is to demonstrate why it can still be concluded that the medicine will likely result in the therapeutic effect described by the indications, despite the gaps and discrepancies in the body of evidence.

A justification can be in the form of a written explanation or the provision of additional supportive evidence (or both).

**When a justification should be provided**

If an evidence package includes sources that do not provide certain details (e.g.,. frequency of dose, dosage form) that are pertinent to establishing relevance to your medicine, a justification should be provided for how the purported effect in those sources can be extrapolated to your medicine.

Where a source includes population groups (e.g.,. adults with a serious disease) that differ from the target population group for the indication e.g.,. generally healthy adults), an evidence-based justification should be provided for how the results observed in the studied population can be extrapolated to your medicine and its target population. In some circumstances, a combination of *in vitro*, non-clinical and clinical data may show that the mechanism of action of an active ingredient works independently of the disease state and any pathophysiological differences of the study participants. In this instance, data from a diseased population may be justified to be generalisable to a healthy population.

Where there are competing datasets, it is important to explain why a particular dataset best represents what your medicine will do e.g.,. in some instances, the differences in results may be due to differences in dosage, the population tested or other aspects of study methodology that do not align with your medicine design.


Where there is data to suggest that certain aspects of a population demographic (e.g.,. diet, gender, age) have an impact on the therapeutic effect that is being examined (e.g.,. enhances intestinal beneficial bacteria growth), justifications should be provided to demonstrate how the results from a specific demographic (e.g.,. adults with a Japanese diet) can be extrapolated to the medicine’s target population (e.g.,. adults with an Australian diet).

Examples of when a justification should be provided in your evidence package may include (but are not limited to):

Where an evidence source:

* is not relevant to your medicine’s design (e.g.,. different ingredients, method of preparation, dosage, target population)
* is not high quality
* has a moderate to high risk of bias
* has a poor study design, low statistical power or low clinical significance
* is not reflective of the evidence landscape
* includes study endpoints that are not relevant to the indication
* does not include details to establish relevance to your medicine’s design and/or determine risk of bias and/or determine data validity

**Figure 6** summarises the overall process for determining the evidence to include in an evidence package.

Figure : Process for determining the evidence sources to include in an evidence package

# Appendices

## Appendix 1: Examples of resources and texts

The TGA does not routinely review the information included in internationally recognised resources and texts (for example: pharmacopoeias or monographs). It is a sponsor’s responsibility to ensure that the sources included in an evidence package are relevant to the medicine and of sufficient quality.

The following list includes examples of internationally recognised texts that may be used to provide support efficacy:

**Monographs**

* Blumenthal M *et al.* (eds) (2000) Herbal Medicine – Expanded Commission E monographs, American Botanical Council, Austin, Texas.
* European Scientific Co-operative on Phytotherapy (ESCOP) series (1996) Monographs on the Medicinal Uses of Plant Drugs, ESCOP, Exeter.
* World Health Organization (WHO) (1999) Monographs on Selected Medicinal Plants, Vol 1, WHO, Geneva.
* European Medicines Agency (EMA) Herbal Monographs: [Medicines | European Medicines Agency (europa.eu)](https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Herbal/field_ema_herb_outcome/european-union-herbal-monograph-254)

**Pharmacopoeias**

* *British Herbal Pharmacopoeia*, British Herbal Medicines Association, West Yorkshire.
* *European Pharmacopoeia*, Council of Europe, Strasbourg.
* *Martindale: the Extra Pharmacopoeia*, Pharmaceutical Press, London.
* The British Pharmaceutical Codex, Pharmaceutical Press, London.
* *The British Pharmacopoeia*, Her Majesty’s Stationary Office, London.
* *The United States Pharmacopoeia and National Formulary*, USP Convention Inc, Rockville, Maryland.
* *Pharmacopoeia of the People’s Republic of China* VOL 1.

## Appendix 2: Case studies

|  |  |
| --- | --- |
| Information | **Note:**  **TGA disclaimer**  The following case studies are hypothetical examples only. The indications do not relate to actual medicines and the evidence packages described do not relate to actual evidence.  The TGA has not assessed whether there is evidence to support the efficacy of medicines with these the indications. They are provided here as a tool to accompany the information included in this guidance document and provide additional clarity to assist sponsors. |

Case study 1: Health benefit does not match

The health benefit investigated in the evidence source does not match the medicine indication.

| Product | Beans Mood Support |
| --- | --- |
| Ingredient/s (per capsule) | *Pinus pinaster* (French Maritime Pine) bark 900 mg |
| Indication/s | Helps support healthy emotional/mood balance |
| **Sponsor’s evidence source** | Sponsor provides a clinical trial study showing that *Pinus pinaster* is effective in reducing visible signs of aging such as fine lines and wrinkles. The sponsor also provides a justification that improving personal perceptions of image is associated with better mental health and therefore reducing wrinkles will support emotional or mood balance. |
| **TGA assessment summary:**  The results of the clinical trial showing the reduction in wrinkles has been incorrectly extrapolated to the potential impact it may have on the emotional/mood balance of the study participants. As such, the clinical trial is not considered applicable to the medicine. | |

Case study 2: Active ingredient dose does not match

The active ingredient dose in the evidence source does not match the medicine.

| Product | Beans AntiFlam |
| --- | --- |
| **Ingredient/s (per capsule)** | Equiv. to *Camellia sinensis* leaf dry (green tea) 20 mg Equiv. to *Curcuma longa* dry rhizome (turmeric) 3 g *Zingiber officinale* (ginger) whole dried root 10 mg |
| **Dose Instructions** | Take one capsule daily with food |
| **Indication/s** | The combination of Beans AntiFlam’s green tea, turmeric and ginger elicits its anti-inflammatory effects. |
| **Sponsor’s evidence source** | Sponsor provides a monograph for *Zingiber officinale* from an internationally recognised health organisation as one of the supporting non-clinical sources of evidence. The monograph states the dose of *Zingiber officinale* dried root to be 17 mg daily, with one of its indications being ‘anti-inflammatory properties’. The sponsor states that that the other active ingredients (that is, green tea, turmeric) also contribute to the product's anti-inflammatory effect. Sponsor did not provide justification as to why this monograph can be extrapolated to their medicine.  (Note: Separate evidence sources were provided for the other active ingredients and were assessed accordingly. This example only focusses on the *Zingiber officinale* and the monograph provided for this ingredient.) |
| **TGA assessment summary:**  The amount of ginger in the monograph is not consistent with the medicine—the sponsor has only stated that the other active ingredients contribute to the medicine's anti-inflammatory effect but did not provide a sufficient justification for why the data in the monograph can be extrapolated to the medicine despite this discrepancy. Therefore, the sponsor has not demonstrated how the monograph is applicable to the medicine. | |

Case study 3: Active ingredient dose does not match

The active ingredient dose in the evidence source does not match the medicine.

| Product | Beans Joint |
| --- | --- |
| **Ingredient/s (per capsule)** | Green-lipped mussel dried 500 mg |
| **Dose Instructions** | Take 1-2 capsules daily |
| **Indication/s** | Helps relieve mild joint aches and pains from mild osteoarthritis |
| **Sponsor’s evidence source** | Sponsor provides a clinical trial paper showing patients taking capsules equivalent to 1000 mg of dried green-lipped mussel per day for their mild osteoarthritis joint pain. |
| **TGA assessment summary:**  This evidence source does not support the dosage of the medicine. The evidence source only examined 1000 mg of dried green lipped mussel, which is equivalent to 2 capsules per day of the sponsor’s medicine. In this particular scenario, a consumer who only takes one capsule of Beans Joint per day will only receive half the dose that was used in the clinical trial. Therefore, the dose referenced in the evidence source is not fully applicable to the medicine. | |

Case study 4: Preparation method does not match

The method of preparation (solvent type/ratio) of the active ingredient in the evidence source does not match the medicine.

| Product | Beans Tonic |
| --- | --- |
| **Ingredient/s (per capsule)** | *Silybum marianum* (milk thistle) 800 mg |
| **ARTG Formulation** | Concentration ratio: 50:1 Plant part: fruit Preparation: extract dry concentrate Equivalent: Silybum marianum (dry) 40 g Extract step solvent: acetone 90%: water 10% |
| **Sponsor’s evidence source** | Sponsor provides information from a well-recognised evidence-based reference text which states the fruit of *Silybum marianum* is extracted with 70% ethanol and 30% water. Sponsor did not provide justification as to why the use of a different extraction solvent was appropriate. |
| **TGA assessment summary:**  The evidence held by the sponsor uses a different extraction solvent at a different ratio to prepare *Silybum marianum*. The profile of phytochemicals extracted into any solvent depends on the solubility of the compound of interest in the solvent of choice.  The sponsor did not provide a justification to demonstrate that similar chemical constituents would be extracted by using the stated acetone: water mixture instead of the ethanol: water mixture. Therefore, in the absence of sufficient justification and/or supporting documents to demonstrate the comparability of the extracted components, this evidence source is not considered applicable to the sponsor’s medicine. | |

Case study 5: Preparation method (raw) does not match

The method of preparation (raw vs extract) of the active ingredient in the evidence source does not match the medicine.

| Product | Beans Root |
| --- | --- |
| **Ingredient/s (per capsule)** | *Panax ginseng* 300 mg |
| **ARTG Formulation** | Concentration ratio: 10:1 Plant part: root  Preparation: extract dry concentrate Equivalent: Panax ginseng (dry) 3 g Extract step solvent: ethanol 80%: water 20% |
| **Sponsor’s evidence source** | Sponsor provides information on the traditional usage of *Panax ginseng* relevant to their product and indication from a well-recognised, evidence-based reference text. The evidence source states *Panax ginseng* root is to be taken in powder form. |
| **TGA assessment summary:**  The *Panax ginseng* in the medicine has undergone chemical processing via ethanol extraction; in contrast, the evidence source provided suggests that the root has only been physically processed i.e. dried, ground and sifted. The use of a solvent extracts certain components of the whole herb material, thereby changing the chemical constituents of the extract in comparison to the whole herb.  The sponsor did not provide any justification to demonstrate that the different method of preparation would result in the same therapeutic effects as the whole herb that has undergone physical processing only.Therefore, as the method of preparation used in the evidence source is not comparable with the method used for *Beans Root*, the therapeutic effect described in the evidence source cannot be extrapolated to the medicine*.* | | |

Case study 6: Dosage form does not match

The dosage form used in the evidence source does not match the medicine.

| Product | Beans Digestive Relief Tablet |
| --- | --- |
| **Dose Instructions** | Take 1 tablet before or with food |
| **Indication/s** | Helps relieve symptoms of medically diagnosed Irritable Bowel Syndrome (IBS). |
| **Sponsor’s evidence source** | Sponsor provides a clinical trial paper trialling a medicine similar to their product, but the study uses a liquid dosage form of the medicine to be taken before or with food. Sponsor did not provide justification as to why this liquid dosage form is applicable to the medicine. |
| **TGA assessment summary:**  Although both medicines are taken orally, the different dosage forms can differentially affect the speed and availability of the active ingredient, potentially leading to different therapeutic effects depending on the mechanism of action of the compound.  The sponsor did not provide scientific justification on how the tablet form of their medicine is equivalent to the liquid form used in the clinical study. In the absence of an appropriate justification, this evidence source is not applicable to the medicine *Beans Digestive Relief Tablet.* | |

Case study 7: Relevant evidence source

The sponsor’s evidence source is relevant to the medicine and indication and is of sufficient quality.

| Product | Beans Vitamin C |
| --- | --- |
| **Indication/s** | Decrease/reduce/relieve symptoms of common cold. |
| **Sponsor’s evidence source** | The sponsor provided RCT study with the following attributes:   * The treatment was identical in formulation, dosage form and dose to the medicine. * The study population for each parallel study arm had 400 participants. Clear baseline demographics and eligibility/exclusion criteria (e.g.,. age, pre-existing health conditions, pre-enrolment medical examination) for participants were reported. * The study was double blinded, and participants were randomised by a third party using a computer-generated randomisation program. Tablets identical in taste and appearance were used in the placebo control group. The authors further provided that due to the common nature of cold symptoms no significant detection bias could be introduced. * An intention to treat (ITT) analysis was included to account for any non-compliance and subject dropouts. * The primary outcome of the study provided a significant effect (p<0.05, CI 22.5 to 25.3) for the reduction/relief of common cold symptoms for the treatment group in comparison to the placebo. * A validated questionnaire tool was used to determine symptom severity; however, as discussed by the authors. the short version of the tool was used. * Clear analyses and statistics were provided for each of the study outcomes, including any non-significant secondary results and compared to findings of existing studies. |
| **TGA assessment summary:**  The presented RCT was relevant to the medicine (dose, target population etc.) and indications. In particular, the clear reporting of the study’s population demographics, eligibility criteria and results between treatments provided clear context to the generalisability of the results to the Australian population.  Clear descriptions of the randomisation methods, allocation concealment and trial design provided clear mitigation for potential bias and confounders. Any negative findings and limitations of the study were sufficiently justified by the sponsor on why the study was still applicable to their indication. Therefore, taking into consideration the robust trial design and relevance of the treatment and outcome to the indication of the medicine, this is a pivotal study and is considered applicable to the medicine. | |

Case study 8: Relevant evidence sources

The sponsor’s sources of evidence are appropriately relevant to the medicine and are of sufficient quality.

| Product | Beans Live-r Well |
| --- | --- |
| **Indication/s** | Traditionally used in Western herbal medicine to help enhance/promote healthy liver function. |
| **Sponsor’s evidence source** | 1. An official Pharmacopeia for Western herbal medicines outlining the history of use of *Silybum marianum* for promoting healthy liver function that exceeds three generations of use (>75 years). The described method of preparation (extract ratio), dose and plant part are consistent with the medicine. 2. A Materia Medica from a reputable source which details its extensive history of use in Western herbal medicine. The dose and preparation such as the extract ratio, plant part and herbal equivalence are all comparable with the medicine. Any minor discrepancies in the extract solvent were sufficiently justified by the sponsor. The source provided a list of recommended indications which were consistent with the traditional indication to help maintain healthy liver function. |
| **TGA assessment summary:**  The presented evidence (1,2) are recognised sources of evidence for traditional Western herbal medicine that establish a history of use in the paradigm exceeding 75 years. Both texts state *Silybum marianum* has a well-established tradition of use in Western herbal medicine for the indication ‘maintenance of healthy liver function’. The reference ingredient in both texts was consistent with the dose and plant part.  Any missing information on the method of preparation in the first text was supplemented and corroborated by the second. The difference in the extract solvent was sufficiently justified by the sponsor that the solvent used for their medicine extracted comparable active components of the herb without the potentially toxic solvent residues. Therefore, the data in the two sources of evidence are considered applicable to the medicine. | |

Case study 9: Relevant evidence sources

The sponsor’s sources of evidence are appropriately relevant to the medicine and are of sufficient quality.

| Product | Beans Policosanol |
| --- | --- |
| **Indication/s** | Helps maintain/support healthy cholesterol |
| **Included in sponsor’s evidence package** | 1. A monograph from an internationally recognised health organisation which describes the potential health benefits from sugar cane wax alcohols on maintaining serum lipid profiles. This potential benefit is described in a way that is relevant to the medicines, i.e. ingredient’s method of preparation, dosage, conditions of use and population to which it is intended for. 2. An evidence-based reference textbook on complementary and alternative medicine that describes the chemistry of policosanol, its natural sources and its beneficial effects on serum lipid concentrations in a way that is relevant to the medicine (including the population to which the medicine is intended for). The book describes policosanol’s current uses in the alternative medicine space, and further describes policosanols’ hypocholesterolemic effects demonstrated in experimental models, healthy volunteers and type II hypercholesterolemic patients. The book also discusses policosanol’s possible mechanisms of action on lowering cholesterol. |
| **TGA assessment summary:**  Both evidence sources constitute reputable sources of scientific information that support the potential effect of policosanol on the maintenance of healthy cholesterol in a way that is relevant to the medicine and the generally healthy population for which it is intended. Therefore, the data in the two sources of evidence are considered applicable to the medicine. | |

Case study 10: Evidence not relevant and/or insufficient quality

The evidence sources in the evidence package are not relevant to the medicine and not of sufficient quality.

| Product | Beans CoQ10 150mg |
| --- | --- |
| **Indication/s** | Helps enhance/promote healthy blood circulation. |
| **Included in sponsor’s evidence package** | 1. A peer reviewed double blinded RCT study consisting of 16 elderly patients in the cardiovascular ward of Singapore General Hospital displayed a statistically significant decrease in symptoms associated with heart failure by improving blood circulation after treatment with CoQ10. The study population included patients with known hypercholesterolemia that were undertaking statin treatment and special dietary restrictions. The study did not include any power calculations to justify the small sample size had adequate sensitivity to detect changes in the primary outcome. 2. A peer reviewed non-systematic review paper which includes summaries of various clinical studies on the potential use of CoQ10. The material also includes pharmacokinetic and safety data of CoQ10 in rodents, with mechanism of action studies performed in *in-vitro* HL-1 cell lines. |
| **TGA assessment summary:**  Evidence (1) was conducted in an elderly patient population with hypercholesterolemia that were undertaking statin treatment. The study parameters (including CoQ10 blood serum levels and blood cholesterol) are known to be significantly altered in the study population compared to the broader healthy population. Although potentially confounding variables, such as special dietary restrictions, were accounted for in the study (via the use of the control group), the lack of such variable in the general population may alter CoQ10’s effectiveness. Further, the study consisted of a very small sample size, with no justification on how this did not impact the accuracy of the study. As such, without sufficient justification, this evidence source is not considered applicable to their medicine.  Evidence (2) was a literature review consisting of both clinical and non-clinical (animal) studies that provided a broad overview on the potential benefits of CoQ10 in cardiovascular health and improving blood flow. It does not clearly define and answer a focussed clinical question with an assessment on the validity of the findings. Although it may be considered applicable to the medicine, it alone does not demonstrate its efficacy. | |

Case study 11: Evidence not relevant and/or insufficient quality

The evidence sources in the evidence package not relevant to the medicine or of sufficient quality.

| Product | Beans Stomach and Bowel Health |
| --- | --- |
| **Ingredient/s** | Cascara dry (sagrada) extract dry concentrate made with 90% ethanol, 10% water. |
| **Indication/s** | Traditionally used in Western herbal medicine to decrease/reduce/relieve constipation. |
| **Included in sponsor’s evidence package** | 1. A monograph from an international regulatory authority showing the ingredient *Cascara dry (sagrada)* that was consistent with the medicine’s dose and preparation. Although it states ‘traditionally used’, it does not specify the tradition of use within the Western Herbal Medicine (WHM) paradigm. 2. A monograph from an internationally recognised health organisation showing the ingredient *Cascara dry (sagrada)* that was consistent with the medicine’s dose and preparation. Does not state the medicine has a tradition of use in any paradigm and only references scientific studies. 3. An official pharmacopeia that states the ingredient *Cascara dry (sagrada)* is used traditionally in WHM for more than three generations. Dose and preparation are consistent with the medicine. However, the provided therapeutic use is for relieving indigestion. 4. A Materia Medica outlining the history of use that well exceeds three generations of use in WHM. The plant species and part of the plant used have been defined but are different from the plant species and part used in the medicine. The method of preparation also states it as a decoction (boiled in water). |
| **TGA assessment summary:**  The presented monographs (1-2) did not specify a tradition of use in Western herbal medicine. The pharmacopoeia (3) states *Cascara dry* (*sagrada*)has an established tradition of use in Western herbal medicine. However, the stated therapeutic use is for the relief from indigestion and its relevance to the traditional indication ‘for relief of constipation’ was not justified by the sponsor.  The ingredient *Cascara dry* (*sagrada)* in the sponsor’s medicine is an extract dry concentrate prepared with 90% ethanol:10% purified water, whereas the materia medica (4) states it is prepared as a decoction. The plant species and plant part were also different to the medicine. The use of different extraction method and/or solvents will result in different chemical constituents with different characteristics.  The sponsor did not provide evidence to demonstrate the equivalence between the preparations or to justify the difference in plant species/starting plant material. Therefore, in the absence of appropriate justifications by the sponsor, these sources of evidence are not applicable to the traditional indication. | |

Case study 12: Evidence sufficient

The clinical study included an appropriate analysis of sample size to detect statistical significance.

| Product | Beans Migraine Aid |
| --- | --- |
| **Indication/s** | Relieve headache symptoms |
| **Sponsor’s evidence source** | Sponsor provides a clinical study trialling a medicine relevant to their product in relieving symptoms of mild migraine. The published paper showed the following attributes:   * The study was a randomised controlled trial conducted in 32 participants – 15 in the placebo and 17 in the treatment group. * The reduction in headache pain at 2 hours after treatment was the primary endpoint for the study. * Power and sample size calculations, based on the expected difference (determined from a previously published study) determined that at least 14 participants were required per treatment arm. This was based on an α-value of 0.05 and 80% power. |
| **TGA assessment summary:**  At first glance, the number of total participants in the study appears quite small. Without sufficient sample size, it is not possible to *reliably* detect a statistically significant effect. However, the results of a previously published study revealed that the standard deviation of the test groups were relatively narrow. Studies where the anticipated population variance of a given outcome variable is small require a smaller number of study participants. Therefore, as the number of participants was greater than the minimum calculated sample size, and the standard deviations observed were similar to the earlier published study, it is likely that the clinical study had enough study participants to have sufficient statistical power to reliably detect a difference between the groups. | |

Case study 13: Appropriate justification

The evidence package included an appropriate justification to support a discrepancy in the formulation between the evidence source and the medicine.

|  |  |
| --- | --- |
| Product | Beans Zinc Plus |
| **Ingredient/s (per tablet)** | Zinc amino acid chelate (bisglycinate) 100 mg  Equiv. to zinc 20 mg |
| **Dose Instructions** | Take 1 tablet daily with food |
| **Included in sponsor’s evidence package** | An evidence source in relation to zinc gluconate. The sponsor also provides bioavailability studies conducted in human subjects comparing the two oral formulations, zinc bisglycinate and zinc gluconate. The study demonstrates that the bioavailability of zinc bisglycinate was greater than that of zinc gluconate. |
| **TGA assessment summary:**  The evidence source used a different type of zinc salt to the sponsor’s product. The sponsor justified the differences in formulation by including an additional reference to display the bioavailability of zinc bisglycinate was at least equal to, or greater than, zinc gluconate. This justification sufficiently demonstrated the relevance of the active ingredient in the evidence source to the sponsor’s medicine. | |

Case study 14: Non-validated measurement method

The clinical study used a measurement method that was taken from another study and not validated.

| Product | Beans hungerdown |
| --- | --- |
| **Indication/s** | Reduce hunger/appetite |
| **Sponsor’s evidence source** | A clinical study using a visual analogue scale (VAS) secondary assessment method [reference: Silverstone *et al*. (1981)] at thirty-day intervals to determine the changes in four parameters associated with the assessment of appetite (‘hunger’, ‘thoughts of food’, ‘urge to eat’, and ‘fullness of stomach’). |
| **TGA assessment summary:**  The method of determining appetite in the clinical study that administered VAS at thirty-day intervals, was inconsistent with the method reported by Silverstone *et al*. (1981), which administered the VAS at hourly intervals.  As the changes to this secondary method of assessment (VAS) were not appropriately validated in the clinical study, and no justification was provided by the sponsor for the validity of the results obtained from this method, the conclusions in the clinical study are not considered to be reliable. | |

Case study 15: Study duration inconsistent

The study duration of the clinical study is inconsistent with the context of use of the medicine and thus does not support the indication.

| Product | Beans joints |
| --- | --- |
| **Ingredient/s** | Willow bark (*Salix alba*) |
| **Indication/s** | Helps relieve mild joint pain temporarily |
| **Sponsor’s evidence source** | A clinical trial reports a long-term pain relief effect in subjects suffering mild joint pain beginning 2 weeks after the initiation of treatment. |
| **TGA assessment summary:**  The evidence source is not considered relevant to the medicine, as long-term for example: pain relief that occurs 2 weeks after treatment, is not considered relevant to the therapeutic benefit described by the medicine’s indication of temporary (and impliedly, immediate) relief. | |

## Appendix 3: Example evidence package for vitamin B12

**Cover page for a listed medicine evidence package**

**Sponsor instructions:**

1. Provide one completed cover page for your evidence package.
2. Attach ‘Critical appraisal/summary/justification of evidence for listed medicines’ document/s for all indications for your medicine.

**1: Identification of listed medicine and sponsor details  
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

|  |  |
| --- | --- |
| Medicine identification | EXAMPLE |
| Medicine name | Beans B12 supplement |
| AUST L | AUSTL XXX |
| Sponsor name | Beans |
| Sponsor contact details (as recorded in eBs) | Name: Mr J Beans Email: JBeans@Beans.com.au Phone: XXXX XXXX |

**2: Listed medicine details  
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

|  |  |
| --- | --- |
| Medicine details | EXAMPLE |
| Dosage form | Tablets, capsules |
| Route of administration | Oral |
| Intended population (e.g.,. age, gender, ethnicity, health conditions) | Healthy adults |
| Recommended dose | One tablet, twice daily |
| Maximum recommended daily dose (MRDD) | Two tablets |
| Directions for use | Use daily or weekly as directed |
| Duration of use (where relevant) | NA |
| Cautions and contraindications | NA |

**3: Listed medicine active ingredients  
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Australian Approved Name (AAN) | Plant/animal part (*where relevant*) | Preparation (*where relevant*) | Equivalent dose | MRDD |
| 1. Cyanocobalamin | NA | NA | 100mcg | 200mcg |

A: Include all relevant ingredient information such as extraction, solvent, concentration, equivalent weight

**4: Listed medicine indication/s details  
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| No. | Indication/sB | Related ingredient/s | Traditional? | Scientific ? | |
| Non-specific? | Specific? |
| 1 | Helps prevent dietary B12 deficiency | B12 | No | No | Yes |
| 2 | Maintain/support vitamin B12 levels in the body | B12 | No | Yes | No |
| 3 | Maintain/support vitamin B12 within normal range | B12 | No | Yes | No |

B: Where the indication is traditional, the indication should use terminology appropriate to the traditional medical paradigm

**5: Additional information  
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Please provide any additional information which may support your evidence package

|  |
| --- |
| Vitamin B12 is a water-soluble vitamin, the largest of the B vitamins and an essential dietary nutrient required for DNA synthesis, normal blood formation, neurological function, and in the regulation of homocysteine[[18]](#footnote-18),[[19]](#footnote-19),[[20]](#footnote-20). It is required for the synthesis of fatty acids in myelin and, in conjunction with folate, for DNA synthesis. It affects cell growth and replication, and the metabolism of carbohydrates, fats and proteins.  The three chemical forms of cobalamin covered in this evidence package (cyanocobalamin, hydroxocobalamin and mecobalamin) all appear to be absorbed, internalised by cells and follow the same intracellular metabolic pathway that converts them into the functional coenzymes methylcobalamin and adenosylcobalamin[[21]](#footnote-21),[[22]](#footnote-22). Therefore, the three chemical forms are considered to be interchangeable. As such, the attached evidence summary applies to all three chemical forms. |

**6: Name and signature of person compiling/submitting data package  
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

|  |  |  |  |
| --- | --- | --- | --- |
| Name | J Beans | | |
| Signature | JBeans | Date | December 2021 |

**Example evidence package for B12: Search strategy and critical appraisal / justification of evidence for a listed medicine**

**Sponsor instructions**:

1. Complete this document for each indication as part of your evidence package. If you have similar indications that you believe are supported by the same references, it is acceptable to include more than one indication per summary.
2. Number each document (Attachment number) and attach to your Evidence package cover page.

|  |  |
| --- | --- |
| Medicine name | Beans B12 supplement |
| AUST L | AUST L XXXX |
| Attachment Number | 1 |

**1: Details of search strategy**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Sponsor instructions**:

Provide details of the literature searches you conducted (e.g.,. systematic, non-systematic) and include details of sourcesA searched, date-range of searchB, search termsC and type of evidenceD

A Provide identifying bibliographic details, exclude duplicate sources and include any website links

B Not applicable for traditional literature

C Include key words and specific exclusion terms

D Traditional (e.g.,. materia medica, pharmacopoeia) or scientific (e.g.,. clinical study, evidence based text, Cochrane review)

|  |  |
| --- | --- |
| Review of systematic reviews and meta-analyses | |
| Date of search | October 2019 |
| Search terms | “vitamin b12 or vitamin b 12 or b vitamin\* or b12 or cyanocobalamin or methylcobalamin or cobalamin or hydroxocobalamin or mecobalamin” **AND** “random\* or placebo or control\* or clinical trial\* AND “(title) meta-analy\* or metaanaly\* or meta reg\* or metareg\* or systematic review\* or meta-review or review of review\* or umbrella or updated review”. |
| Databases searched | * Cochrane database of systematic reviews * Health Technology Assessment Database * AMED (Allied and Complementary Medicine) * PsycINFO * Embase * MEDLINE |
| Date range for search | Inception to 7 October 2019 |
| Inclusion/exclusion criteria (where relevant) | Inclusion criteria for studies were:   * Systematic reviews and/ or meta-analyses of human clinical trials * B12 used in intervention studies for any diseases/conditions and healthy functioning * Where interventions included more than one active ingredient, B12 had to be the main active ingredient. * All age ranges of relevance ie children, adults and elderly people, pregnant and lactating women * Healthy and clinical populations (including vitamin deficiency) * English language   Exclusion criteria for studies were:   * Studies using parenteral route of administration * Interventions studies for treatment of cancer. Other serious forms of disease were still retained to verify if they might be used to justify some permitted indications. |
| Number and type of articles retrieved | 30 (systematic reviews or meta-analyses) |
| **Non-systematic search of international monographs and reference texts** | |
| Date of search | October 2019 |
| Search terms | Vitamin B6 |
| References searched | * EU Register on nutrition and health claims * European Food Safety Authority scientific opinions * Health Canada monographs * British Pharmacopoeia * Nutrient Reference Values for Australia and New Zealand – Including Recommended Dietary Intakes (2006) * Braun L, Cohen M. Herbs & Natural Supplements – An evidence-based guide 4th Edition (Volume 2). Chatswood: Elsevier Australia; 2014. * Combs Jr GF, McClung JP. The Vitamins: Fundamental Aspects in Nutrition and Health (Fifth Edition). Cambridge (Massachusetts): Academy Press/ Elsevier; 2017. * Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate Other B Vitamins and Choline. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington: National Academies Press; 1998. * The additional indications potentially supported by reasonable (clinical or non-clinical) evidence as they have been noted in other national monographs will then be searched for randomised controlled trials as part of Step 3 and integrated within our list of potential indications as deemed appropriate in light of the most recent evidence. |
| Date range for search | NA |
| Inclusion/exclusion criteria (where relevant) | NA |
| Number and type of articles retrieved | NA |
| **Search of randomised controlled clinical trials (RCTs)** | |
| Date of search | March 2020 |
| Search terms | “vitamin b12 or vitamin b 12 or b vitamin\* or b12 or cyanocobalamin or methylcobalamin or cobalamin or hydroxocobalamin or mecobalamin”  **AND** “random\* or placebo or control\* or clinical trial\*. |
| Databases searched | * Cochrane database of systematic reviews * Health Technology Assessment Database * AMED (Allied and Complementary Medicine) * PsycINFO * Embase * MEDLINE |
| Date range for search | Inception to March 2020 |
| Inclusion/exclusion criteria (where relevant) | Inclusion criteria for studies were:   * Randomised controlled human clinical trials for pre-specified indications * B12 used in intervention studies for any diseases/ conditions and healthy functioning * Where interventions included more than one active ingredient, B12 had to be the main active ingredient. * All age ranges of relevance ie children, adults and elderly people, pregnant and lactating women * Healthy and clinical populations * English language    Exclusion criteria for studies were:   * Studies using parenteral route of administration * Non-randomised, non-controlled intervention studies   Once clinical trial papers were assessed for relevance they were evaluated with the Cochrane ROB tool2 and determined whether they were sufficiently robust to support a permitted indication. High ROB were excluded, Low ROB and those with ‘Some concern’ were retained. |
| Number and type of articles retrieved | 27 (RCTs) |
| **Non-systematic search of scientific literature that provides support to additional claims not directly supported through human clinical trials** | |
| Date of search | NA |
| Search terms | A review of the science underpinning an indication was undertaken to provide appropriate context for the critical analysis discussion, particularly in relation to physiological supportive functions of vitamin B12. |
| References searched | * Monographs * Textbooks * Scientific literature |
| Date range for search | NA |
| Inclusion/exclusion criteria (where relevant) | NA |
| Number and type of articles retrieved | NA |

**2: Critical appraisal including search findings and results (and justification where necessary), credibility, relevance and consistency for each indication and/or claim.  
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Sponsor instructions:**

* Provide a critical analysis of the evidence identified in your literature search, as it relates to your medicine’s indication/s, to demonstrate how the balance of evidence supports the efficacy or tradition of use of your medicine. Your analysis should consider all identified evidence items (referenced), positive or negative, and explain how they support the efficacy of your medicine.
* If there are any information gaps or evidence that is inconsistent (e.g.,. diseased population) with your medicine’s indication you should include a justification based on the totality of your evidence.

|  |
| --- |
| **Indication/s: (Include full wording and the indication reference number/s from your cover page).** |
| 1. Helps prevent dietary B12 deficiency 2. Maintain/support vitamin B12 levels in the body 3. Maintain/support vitamin B12 within normal range |

| **Critical appraisal of evidence** |
| --- |
| A 2013 systematic review and meta-analysis[[23]](#footnote-23) included 49 studies undertaken up to 2010 that measured vitamin B12 status and examined RCTs, prospective cohort studies, nested case-control studies and cross-sectional studies using food sourced (dietary or fortified foods) or supplemental vitamin B12 by oral administration. The chemical form of B12 investigated in these studies was not specified. Twenty-four studies compared medicines containing vitamin B12 to placebo. Results from studies that investigated vitamin B12 as part of a multi-ingredient supplement were considered relevant to the above indications as the absorption of B12 is unlikely to be confounded by concomitant supplementation in generally healthy individuals without B12 malabsorption conditions (and therefore intake of other vitamins and minerals is unlikely to impact the absorption of dietary B12 into the blood stream[[24]](#footnote-24)). The dosage of vitamin B12 ranged from 9 µg/day to 1000 µg/day and varied in duration from 4 to 104 weeks. The pooled dose-response data between vitamin B12 intake and status from all studies indicated that a doubling of the vitamin B12 intake increased vitamin B12 concentrations by 11% (95% CI: 9.4%, 12.5%). The meta-analysis of RCT data showed a stronger dose-response relationship than the observational studies. The increase in vitamin B12 was larger for studies in elderly persons (13% - 27 studies; mean age >65 years old) than in adults (8% - 29 studies; mean age >18 and ≤64 years old) possibly explained by low-baseline concentrations in the elderly.  One of the first effects of a deficiency of vitamin B12 is to inhibit a vitamin B12 dependent enzyme (methylmalonic CoA mutase) which leads to an increase in methylmalonic acid (MMA)[[25]](#footnote-25). The 2013 systematic review[[26]](#footnote-26) demonstrated that the dose-response relationship between vitamin B12 intake and serum MMA concentrations indicated a decrease in MMA of 7% (95% CI: -10%, -4%) for every doubling of the vitamin B12 intake. However, the authors found substantive heterogeneity between studies and noted that they had different study designs, different follow-up times, different doses or forms of dietary vitamin B12 intake, different analytical methods to assess vitamin B12 in blood, and differences in populations studied. Such differences represented real uncertainty in modelling B12 concentrations as a function of B12 intake. Nevertheless, the meta-analysis of RCTs and observational data overall, demonstrates that oral supplementation with vitamin B12 through enriched foods, drinks, or capsules in the general population increases blood levels of vitamin B12, thus reducing the likelihood of dietary deficiency.  Individual RCTs undertaken since the 2013 systematic review support the observation that vitamin B12 supplementation increases vitamin B12 status in special populations at risk of vitamin B12 deficiency. This included an RCT that studied Bangladeshi women (n=68, 11-14 weeks pregnant) taking 250 µg/day vitamin B12 (type unspecified) throughout pregnancy and 3 months postpartum[[27]](#footnote-27). Both treatment and placebo groups also received 60 mg iron and 400 µg folate as part of the routine care of pregnant women which continued 3-months postpartum. At baseline in both groups, 39.7% of participants were categorised as having ‘marginal B12 deficiency’ (150–220 pmol/L) and 26.4% as ‘B12 deficient’ (<150 pmol/L). There was a significant increase in median plasma B12 levels in the mothers 72 h post-delivery (267 vs. 142 pmol/L, p < 0.001) and 3 months post-partum (416 vs. 242 pmol/L, p < 0.001) when compared to placebo. Supplementation also significantly lowered median MMA (198 vs. 305 nmol/L, p < 0.001) at 72-h post-delivery and (191 vs. 294 nmol/L, p < 0.001) at 3-month postpartum in mothers compared with placebo group.  A 2014 RCT investigated South Asian women in New Zealand (n=62) of childbearing age (18-50 years old) taking 6 µg/day (cyanocobalamin) for 6 months. At baseline, 48% were insufficient or deficient in serum B12 and 51% were insufficient or deficient in holotranscobalamin in both the placebo and treatment groups. The serum B12 and holotranscobalamin levels were significantly improved in women with inadequate dietary intake who had high compliance (>76%) to supplement intake when compared with placebo[[28]](#footnote-28).  A 2019 Italian study in vegans and vegetarians (n=36) who had marginal B12 deficiency (<220 pmol/L), showed that cyanocobalamin supplementation with two different sublingual doses (350 µg/week given as 50 µg/day and 2,000 µg/week given as a single dose) both restored vitamin B12 status (>240 pmol/L) and improved other metabolic biomarkers (including holotranscobalamin and MMA) over 12 weeks compared to baseline (as a placebo group could not be included for ethical reasons)[[29]](#footnote-29).  A 2005 study in healthy older people (n=117; >70 years old) with mild B12 deficiency (serum vitamin B12 level of 100 to 300 pmol/L and a methylmalonic acid level of 0.26 μmol/L or greater) in the Netherlands assessed the effects of five doses of vitamin B12 (2.5, 100, 250, 500 and 1,000μg/day) for 16 weeks to normalise biomarkers of the deficiency[[30]](#footnote-30). Daily supplementation with 2.5, 100, 250, 500, or 1000 μg/day of cyanocobalamin resulted in reductions in MMA concentrations to below the reference interval of 0.26 μmol/L in 21%, 38%, 52%, 62%, and 76% of the participants, respectively. The analysis demonstrated that the lowest daily oral dose of cyanocobalamin that resulted in 80% to 90% of the maximum reduction in MMA concentrations varied from 647 to 1032 μg/day. On average, such doses of cyanocobalamin reduced plasma MMA concentrations by approximately 33%. The results also showed that daily oral doses of 527 to 759 μg/day of cyanocobalamin resulted in 80% to 90% of the estimated maximum increase in holoTC concentrations.  The individual trials above included populations that may not be entirely representative of the Australian population. However, the body of evidence taken as a whole, shows that oral supplementation with vitamin B12 can increase plasma B12 levels and decrease MMA levels irrespective of differences in populations studied. While there is some evidence of genetic variants affecting vitamin B12 status in particular ethnicities[[31]](#footnote-31), in the absence of information establishing significant impact on absorption in a particular ethnic group, the results from the RCTs are considered to be applicable to a generally healthy Australian population. For these reasons, the evidence presented in this statement is sufficient to establish that supplementation with vitamin B12 would maintain B12 levels in the bloodstream and within a normal range in generally healthy individuals with no B12 malabsorption conditions. Therefore by extrapolation, oral supplementation with vitamin B12 is likely to reduce the risk of a vitamin B12 dietary deficiency and thus assist in its prevention. This evidence however, does not extend to the treatment of either a dietary or clinical vitamin B12 deficiency. |

**Version history**

|  |  |  |  |
| --- | --- | --- | --- |
| Version | Description of change | Author | Effective date |
| V1.0 | Original publication | TGA, Office of Complementary Medicines (OCM) | October 2001 |
| V1.1 | Change of format | TGA, OCM | April 2011 |
| V2.0 | Revision | TGA, OCM | March 2014 |
| V2.1 | Row 1, Table 16, page 41 correction of BMI range to state 25-30kg/m2 | TGA, OCM | July 2014 |
| V3.0 | * Reviewed to incorporate amendments to the Act that came into effect March 2018 that introduced permitted indications for listed medicines and the assessed listed pathway. * Updated indication examples and updated information on biomarker indications to be consistent with the permitted indications for listed medicines. * Removal of duplicate information available in other guidance material on the TGA website (e.g.,. ARGCM, ARGATC). * Formatting changes, correction of: links; typographical; and grammatical errors. | TGA, Office of Complementary & Over the Counter Medicines (COMB) | January 2019 |
| V4.0 | * Restructured - no longer parts A and B, instead has been put into sections that align with the process a sponsor would follow. * Added information to consider when undertaking a critical appraisal of evidence. * Updated the types of sources of evidence and the levels of evidence. * Added information relating to non-systematic searches to the literature search section. * Added an example of a literature search strategy. * Updated statistical analysis section. * Clarification of the specific/non-specific classification and the removal of this classification for traditional indications. * New decision tool to assist classification of specific/non-specific indications. * Updated evidence requirements for supplementation claims and indications. * Updated the weight loss section to differentiate between long-term and short-term weight loss. * Update to the minimum levels of evidence requirements for traditional and scientific indications. * Updated/ new figures, tables and decision trees. * Removed references to journal impact factors. * Added a justification section and examples of where a sponsor would provide a justification as part of their evidence package. * Evidence package checklists have been removed (a link to the TGA website provided) as these are under currently review. * Added an appendix with theoretical case studies. * Added an example of an evidence package. | TGA, COMB | March 2022 |

|  |
| --- |
| **Therapeutic Goods Administration** |
| PO Box 100 Woden ACT 2606 Australia  Email: [info@tga.gov.au](mailto:info@tga.gov.au) Phone: 1800 020 653 Fax: 02 6203 1605  [**https://www.tga.gov.au**](https://www.tga.gov.au) |
| Reference/Publication # D21-30581111 |

1. Adapted from European Medicines Agency “[Efficacy and Effectiveness Models](https://www.ema.europa.eu/en/documents/presentation/presentation-efficacy-effectiveness-models_en.pdf)” [↑](#footnote-ref-1)
2. National Health Medical Research Council. [Levels of evidence and grades for recommendations for developers of guidelines](https://www.nhmrc.gov.au/sites/default/files/images/NHMRC%20Levels%20and%20Grades%20(2009).pdf) 2009. [↑](#footnote-ref-2)
3. Schulz et al. (2010). CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. Annals of Internal Medicine 152. [↑](#footnote-ref-3)
4. Koepsell, T & Weiss, N (2003). Epidemiologic Methods: Studying the occurrence of illness. Oxford University Press, New York. [↑](#footnote-ref-4)
5. Knowler WC, Barrett-Connor E, Fowler SE, et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 346(6):393–403. [↑](#footnote-ref-5)
6. Wing RR, Lang, W, Wadden TA, et al. (2011) Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 34:1481-1486. [↑](#footnote-ref-6)
7. European Medicines Agency (2007). Guideline on clinical evaluation of medicinal products used in weight control (CPMP/EWP/281/96). London [↑](#footnote-ref-7)
8. Franz M, *et al*. (2007). Weight-loss outcomes: A systematic review and meta-analysis of weight- loss clinical trials with a minimum of 1-year follow-up. Journal of the American Dietetic Association 107: 1755-1767. [↑](#footnote-ref-8)
9. Wu T, *et al*. (2009). Long-term effectiveness of diet-plus-exercise interventions vs. diet only interventions for weight loss: a meta-analysis. Obesity Reviews 10: 313-323. [↑](#footnote-ref-9)
10. Sacks F, *et al*. (2009). Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. New England Journal of Medicine 360(9): 859-873. [↑](#footnote-ref-10)
11. Rose G and Day, S (1990). The population mean predicts the number of deviant individuals. British Medical Journal 301: 1031-1034 [↑](#footnote-ref-11)
12. European Medicine Agency (2017) Guideline on clinical evaluation of medicinal products used in weight management. <https://www.ema.europa.eu/en/clinical-evaluation-medicinal-products-used-weight-control> [Accessed 4 July 2019] [↑](#footnote-ref-12)
13. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2007). Guidance for industry developing products for weight management. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-products-weight-management-revision-1> [Accessed 5 July 2019]. [↑](#footnote-ref-13)
14. Jensen MD, Ryan DH, Apovian CM, et al. (2014) 2013 AHA/ACC/TOS guide­line for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation*. 129(25 Suppl 2):S102–S138. [↑](#footnote-ref-14)
15. National Health and Medical Research Council (2013) Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. <https://www.nhmrc.gov.au/about-us/publications/clinical-practice-guidelines-management-overweight-and-obesity> [Accessed 5 July 2019] [↑](#footnote-ref-15)
16. Franz MJ, VanWormer JJ, Crain AL, et al. (2007) Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. *J Am Diet Assoc*. 107(10):1755-67. [↑](#footnote-ref-16)
17. Sacks FM, Bray GA, Carey VJ, et al. (2009) Comparison of weight-loss diets with different compositions of fat, protein and carbohydrates. *N Engl. J Med.* 360(9):859-873. [↑](#footnote-ref-17)
18. National Institutes of Health Office of Dietary S. Vitamin B12 Fact Sheet for Health Professionals USA: US Department of Health and Human Services; 2020 [Available from: <https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/> [↑](#footnote-ref-18)
19. Allen LH, Miller JW, de Groot L, Rosenberg IH, Smith AD, Refsum H, et al. Biomarkers of Nutrition for Development (BOND): Vitamin B-12 Review. The Journal of nutrition. 2018;148(suppl\_4):1995s-2027s. [↑](#footnote-ref-19)
20. NHMRC, New Zealand Ministry of Health. Nutrient Reference Values Vitamin B12. Canberra (Australia): National Health and Medical Research Council (NHMRC); 2006. [↑](#footnote-ref-20)
21. Paul C, Brady DM. Comparative Bioavailability and Utilization of Particular Forms of B(12) Supplements With Potential to Mitigate B(12)-related Genetic Polymorphisms. Integrative medicine (Encinitas, Calif). 2017;16(1):42-9. [↑](#footnote-ref-21)
22. Obeid R, Fedosov SN, Nexo E. Cobalamin coenzyme forms are not likely to be superior to cyano- and hydroxyl-cobalamin in prevention or treatment of cobalamin deficiency. Molecular nutrition & food research. 2015;59(7):1364-72. [↑](#footnote-ref-22)
23. Dullemeijer C, Souverein OW, Doets EL, van der Voet H, van Wijngaarden JP, de Boer WJ, et al. Systematic review with dose-response meta-analyses between vitamin B-12 intake and European Micronutrient Recommendations Aligned's prioritized biomarkers of vitamin B-12 including randomized controlled trials and observational studies in adults and elderly persons. The American journal of clinical nutrition. 2013;97(2):390-402. [↑](#footnote-ref-23)
24. Obeid R, Fedosov SN, Nexo E. Cobalamin coenzyme forms are not likely to be superior to cyano- and hydroxyl-cobalamin in prevention or treatment of cobalamin deficiency. Molecular nutrition & food research. 2015;59(7):1364-72. [↑](#footnote-ref-24)
25. Combs GF, McClung JP. Vitamin B12. In: Combs GF, McClung JP, editors. The Vitamins: Fundamental Aspects in Nutrition and Health. 5 ed. Cambridge (Massachusetts): Academic Press; 2017. p. 431-52. [↑](#footnote-ref-25)
26. Dullemeijer C, Souverein OW, Doets EL, van der Voet H, van Wijngaarden JP, de Boer WJ, et al. Systematic review with dose-response meta-analyses between vitamin B-12 intake and European Micronutrient Recommendations Aligned's prioritized biomarkers of vitamin B-12 including randomized controlled trials and observational studies in adults and elderly persons. The American journal of clinical nutrition. 2013;97(2):390-402. [↑](#footnote-ref-26)
27. Siddiqua TJ, Ahmad SM, Ahsan KB, Rashid M, Roy A, Rahman SM, et al. Vitamin B12 supplementation during pregnancy and postpartum improves B12 status of both mothers and infants but vaccine response in mothers only: a randomized clinical trial in Bangladesh. European journal of nutrition. 2016;55(1):281-93. [↑](#footnote-ref-27)
28. Mearns GJ, Koziol-McLain J, Obolonkin V, Rush EC. Preventing vitamin B12 deficiency in South Asian women of childbearing age: a randomised controlled trial comparing an oral vitamin B12 supplement with B12 dietary advice. European journal of clinical nutrition. 2014;68(8):870-5. [↑](#footnote-ref-28)
29. Del Bo C, Riso P, Gardana C, Brusamolino A, Battezzati A, Ciappellano S. Effect of two different sublingual dosages of vitamin B(12) on cobalamin nutritional status in vegans and vegetarians with a marginal deficiency: A randomized controlled trial. Clinical nutrition (Edinburgh, Scotland). 2019;38(2):575-83. [↑](#footnote-ref-29)
30. Eussen SJ, de Groot LC, Clarke R, Schneede J, Ueland PM, Hoefnagels WH, et al. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. Archives of internal medicine. 2005;165(10):1167-72. [↑](#footnote-ref-30)
31. Surendran S, Adaikalakoteswari A, Saravanan P, Shatwaan IA, Lovegrove JA, Vimaleswaran KS. An update on vitamin B12-related gene polymorphisms and B12 status. Genes & nutrition. 2018;13:2. [↑](#footnote-ref-31)